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SUMMARY 
 
This dissertation discusses Amyotrophic Lateral Sclerosis (ALS) and the progress, or lack 
thereof, in its treatment thus far. ALS is a neurodegenerative disorder characterised by the 
degeneration of both upper motor neurons in the motor cortex and lower motor neurons 
connecting the spinal cord and brain stem to muscle fibers. The prognosis is poor with death 
occurring approximately 3 years after the detection of symptoms. Numerous therapeutic 
agents have been tested in clinical trials but only one drug, riluzole, has received FDA 
approval over the years.  
A review examining various ALS treatment options previously investigated explains how 
most of these have failed possibly due to, amongst many other factors, poor clinical trial 
designs as well as the difficulty in delivering therapeutic agents across the blood-brain 
barrier. Therefore, extensive exploration into the disorder and the barriers encountered when 
designing treatment for it is necessary in order to unearth a solution to this problem. This 
dissertation proposes that nanotechnology increases the chances of improving the efficiency 
of therapeutic agents previously tested with minimal or no positive results. Nanotechnology 
has been investigated in other neurodegenerative disorders such as Alzheimer’s disease 
and Parkinson’s disease and although most of these studies are at a foundation level, they 
are showing a lot of promise. 
In an attempt to tackle the difficulties presented by the treatment of ALS, a nano-enabled 
drug delivery system was formulated to deliver amantadine in the brain. This delivery system 
comprises of poly(D,L-lactide)-Eudragit® L100 nanospheres prepared by the double solvent 
evaporation technique and conjugated to the chelating ligand diethylenetriamine penta-
acetic acid (DTPA). A design of experiments approach was used to formulate an optimal 
nanosphere formulation subsequent to preformulation studies. Fifteen formulations were 
prepared using the Box-Behnken design and were tested for particle size, drug entrapment 
efficiency, mean dissolution time and zeta potential. The optimal formulation was determined 
according to the suitable responses and was followed by insertion into an N-
Vinylcaprolactam ε-caprolactone injectable hydrogel. The hydrogel prepared responded to 
temperature changes and was developed to form a solid at body temperature.  
In vitro and ex vivo tests were performed on the drug delivery system. Motor neuron cells 
were used to investigate the cytotoxicity and the cellular uptake of the delivery system.  
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CHAPTER ONE 
BACKGROUND AND MOTIVATION FOR THIS STUDY 
 
1.1. Introduction to Amyotrophic Lateral Sclerosis 
Motor neuron disease (MND) refers to a group of progressive neurodegenerative disorders 
which are distinguished by the deterioration of upper motor neurons and/or lower motor 
neurons (Leigh and Ray-Chaudhuri, 1994). In upper motor neuron degeneration, the 
condition is known as Primary Lateral Sclerosis and presents as Babinski signs, Hoffmann 
signs and excessive tendon reflexes. Progressive Spinal Muscular Atrophy is the term used 
to describe lower motor neuron degeneration. Symptoms for this condition are muscle 
atrophy, fasciculation and weakness (Rowland and Shneider, 2001). Additionally, a disorder 
known as Amyotrophic Lateral Sclerosis (ALS) results in the degeneration of both upper and 
lower motor neurons and has the most cases reported on it. The frequency of this disease is 
approximately 2 in 100 000 with an average age of onset of 58 years (Talbot, 2002). The 
expected survival from the initiation of the symptoms is 3 years. In approximately 90% of the 
cases, the disease occurs sporadically (Sporadic ALS) whereas the remaining 10% is 
inherited or familial (Familial ALS) (Shaw, 1999).  
There is currently uncertainty regarding the pathogenesis of motor neuron degeneration. 
Mechanisms which appear to contribute to the neurodegenerative progression comprise of 
protein aggregation, glutamatergic toxicity, mitochondrial dysfunction, oxidative stress, 
neuroinflammation, cytoskeletal derangements, growth factor dysregulation, apoptosis as 
well as high expression of copper/zinc superoxide dismutase (Cu/Zn SOD1) (Shaw, 1999; 
Bedlack et al., 2007).  
The only drug which is approved by the USA Food and Drug Administration (FDA) for the 
treatment of MND is riluzole. It is a glutaminergic transmission modulator which inhibits the 
release of glutamate at the presynapsis. It also non-competitively inhibits the action of 
excitatory amino acids postsynaptically. Riluzole has additional mechanisms of action 
including the inactivation of voltage-gated sodium channels and activation of G-protein-
dependent processes (Iłżecka, 2003).  
In a study by Bensimon (1994), survival rate, being the primary end point, proved to be 
considerably improved with the use of riluzole. This study showed that riluzole had greater 
effects in patients with ALS of bulbar onset than those of limb onset. Therefore, according to 
this study, there is a dependence on site of onset of disease for a larger and substantial 
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effect of riluzole. Treatment with riluzole showed major therapeutic effects over the first 12 
months of use and a decline thereafter ensued. An enhanced and infinite way of treating 
neurodegenerative disorders is therefore needed in order to achieve improved results. The 
blood-brain barrier (BBB) is one of the factors that require attention when developing new 
therapies as it contributes to the minimal success achieved in finding an effective treatment. 
1.2. The physiology of the BBB 
The BBB is a monolayer of cells that regulates the passage of molecules between the CNS 
and the blood. The restrictive properties of the BBB are dire and emulate that of a 
continuous cell membrane. The tight junction (also referred to as a zonula occludens) is a 
site where the membranes of two cells come so close together that the membranes of the 
contacting cells appear to be fused (Figure 1.1). Tight junctions act as a barrier, preventing 
materials from passing between two interacting cells. These junctions present as an 
uninterrupted stretch of sheets completely encircling the cell. Molecules therefore, cannot 
pass from one side of the sheet to the other by squeezing between cells. Alternatively, these 
molecules must go through a cell, and hence the cell can regulate their passage. The 
endothelial cells that create the barrier at the capillaries and arterioles as well as at the 
epithelial cells that make up the barrier at the choroid plexus direct the homeostatic 
environment of the CNS, coordinate the route of peptides and regulatory proteins, and 
manage the access of metabolic fuels, neurotransmitter precursors, and essential nutrients 
into the CNS. Additionally, the cells that mould the BBB have active enzymes, supply 
cytokines and nitric oxide, and are able to secrete toxic molecules. Consequently, the BBB 
goes beyond its role as a physical barrier and is aptly observed as a regulatory boundary 
and progressively established to be a target for therapeutic interventions. (Banks, 1999; 
Francis et al., 2003) 
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Figure 1.1. The blood–brain barrier (BBB). The BBB is created by the tight junctions made 
up of endothelial cells lining blood vessels in the brain, constructing a barrier between the 
circulation and the brain parenchyma (Francis et al., 2003) 
 
1.3. Rationale and Motivation for the Study 
The penetration of the BBB is essential in obtaining effective treatment of any CNS 
disorders. Currently, the conventional methods are not designed to specifically target the 
affected sites nor are they able to adequately bypass the BBB. Consequently, the prescribed 
doses of these particular agents have to be increased to levels that have a likelihood of 
reaching therapeutic concentrations at the intended site. This therapeutic dose, however, 
becomes toxic to the rest of the body and in due course insignificant therapeutic effects are 
achieved.  
 
Polymers have been used extensively in the preparation of drug delivery systems and are an 
enhanced alternative to the commonly used routes of drug administration. Nanospheres can 
be used to create a system that will deliver therapeutic agents in a controlled process. This 
can be achieved by distributing the therapeutic agent into the nanocapsule’s matrix. The 
nanocapsule is able to control the release of the drug because of its biodegradation features 
that allow a more predictable control of drug release kinetics (Peracchia et al., 1997; Modi et 
al., 2010). Greater therapeutic efficiency is accomplished when using nanospheres as they 
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provide a protective environment for the drug. This results in the drug remaining in its active 
conformation until it reaches its target site (Peracchia et al., 1997). Furthermore, in order to 
produce nanospheres which will be endocytosed by neuron cells, chelating ligands can be 
strategically conjugated onto these nanospheres resulting in a targeted complex. Drug-
loaded ligand-bound nanospheres (DLLBN) can be injected at the site of action; however, 
the incorporation of these nanospheres into a biodegradable polymeric biomaterial 
(hydrogel) is beneficial for targeted drug delivery and is synergistic in accomplishing 
controlled release of the drug. Furthermore, the integration of biodegradable polymers in the 
formulation, evades the need for surgical procedures in order to remove the material once its 
drug-load has been exhausted. Injectable scaffolds, which are cross-linked forms of 
hydrophilic polymers, have shown to be biomaterials with a prospective for use in the 
biological and medical fields (Peppas et al., 2006). The use of a thermosensitive hydrogel as 
a carrier of the drug-loaded nanospheres is proposed to be an effective drug delivery 
system. The approach would be to intracranially inject the DLLBN-carrying implantable 
hydrogel as opposed to the conventional systemic therapy. 
Since there is currently only one (inadequate) FDA approved drug for the treatment of ALS, 
looking elsewhere for an alternative therapeutic agent to incorporate in this system, an agent 
that has perhaps been overlooked in the past, brings about the possibility of much needed 
progress in the treatment of ALS. 
Amantadine, an antiviral drug, is amongst a series of drugs indicated for the treatment of 
influenza A. However, its mechanism of action with regards to the treatment of Parkinson’s 
disease appears to be isolated from that of the treatment of influenza. Amantadine induces 
dopamine synthesis and release, and blocks the reuptake of dopamine to increase 
availability for dopaminergic receptor activation. It is also a potent antagonist at the N-methyl 
D-aspartate (NMDA) receptor. In a study by Parkes et al. (1970), amantadine significantly 
improved the patients’ tremor, hypokinesia as well as their appearance showing its worth in 
patients with Parkinson’s disease. It also reduced dyskinesia in patients with Huntington’s 
disease (Calon et al., 2003). Amantadine shows partial neuroprotective properties in the 
MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropoyridine) model of Parkinson’s disease 
demonstrating valuable effects on disease progression (Bonuccelli and Del Dotto, 2006). 
According to Guttman et al. (2003), patients requiring minimal treatment should consider 
using amantadine. It should, however, be used with caution in elderly patients as they are 
much more susceptible to CNS effects such as confusion (Guttman et al., 2003). 
Amantadine is better tolerated in younger patients and is beneficial as a first-line therapy. It 
is also suitable for wearing-off phenomenon which occurs initially in Parkinson’s disease 
patients, thus reducing motor oscillations. 
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Oral amantadine is well absorbed by the gastrointestinal tract (GIT) and according to the 
excretion rate has a comparatively long half-life. The rate of excretion is dependent on the 
dose administered (Bleidner et al., 1965; Parkes et al., 1970). Blood levels of amantadine 
reach a peak 4 hours following oral administration of 2.5mg/kg. Up to 92% of amantadine is 
excreted unchanged showing minimal metabolism. Side-effects caused by amantadine 
include insomnia, depression, hallucinations, nausea, constipation, orthostatic hypotension 
and dizziness (Millet et al., 1981). This extensive list of undesired side-effects can lead to 
non-compliance from patients and therefore the design of a system that would accomplish 
minimal adverse events would be exceedingly advantageous. This would necessitate an 
intracellular delivery system that would have negligible contact with the GIT, for instance. 
There is currently insufficient literature on the use of amantadine in ALS. This creates an 
opportunity to develop a novel, targeted intracellular drug delivery that will be successful in 
ALS clinical trials and will eventually become a useful treatment in clinical practice. 
Moreover, one of the proposed pathogenesis of sporadic ALS, according to Rowland and 
Schneider (2001), is persistent viral infection. This is therefore an additional reason to 
explore the use of amantadine as an alternative treatment of ALS because of its foremost 
antiviral property. 
 
1.4. Proposed Drug Delivery System for ALS 
The polymer based delivery system was to be prepared using amantadine-loaded 
nanospheres homogeneously incorporated within an injectable thermosensitive hydrogel 
which would be directly as depicted in Figure 2.1. The nanospheres were proposed to be 
formulated employing a blend of poly-DL-lactide and a polymethacrylate. The 
thermosensitive hydrogel would be prepared using ε-caprolactone and N-vinylcaprolactam. 
The nanosphere-hydrogel composite would be injected into the target site, where the 
thermosensitive gel would react to the increase in temperature and transition from a liquid to 
a sol implant that would gradually disintegrate, releasing the nanospheres to be taken up by 
motor neuron cells, mediated by DTPA (chelating ligand). The nanospheres would then 
release amantadine which would increase dopamine levels while the DTPA removes ions 
hypothesised to play a role in the oxidative stress theory of ALS. 
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Figure 1.2:  A schematic of the proposed drug-loaded ligand-bound nanosphere system  
  
 
1.5. Aims and Objectives 
The aim of this study was to design a ligand-bound nanostructure for optimal intracellular 
drug delivery, carried by a hydrogel, and incorporating the antiviral, amantadine, as the 
model drug for the treatment of ALS. 
 
This aim was achieved by meeting the following objectives: 
1. Synthesis of drug-free and drug-loaded nanospheres using poly (DL-lactide) as well 
as a polymethacrylate (Eudragit® L100) and conjugation of chelating ligand on the 
surface of nanospheres 
2. Morphology observation and characterisation of the nanospheres 
3. In vitro drug entrapment and release studies for nanospheres 
4. Preparation of polymeric injectable scaffold and integration of nanospheres within the 
polymeric injectable scaffold 
5. Morphology and characterisation of intact drug delivery system 
6. In vitro drug release studies of intact delivery system 
7. Investigation of the extent to which the NSC-34 cell-line was able to absorb 
amantadine-nanospheres and the toxicity thereof. 
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1.6. Overview of the Dissertation 
Chapter one begins with an introduction to Amyotrophic lateral sclerosis (ALS), its 
prevalence, as well as the various theories surrounding the pathophysiology of the disease. 
It outlines the rationale for this study, looking at the blood-brain barrier as one of the 
obstacles to developing an effective treatment and introduces nanotechnology as a possible 
solution. The chapter also delineates the aims and objectives of this research and the 
potential benefits that may arise from this research. 
 
Chapter two is a literature review delving deeper into the pathophysiology of ALS and the 
various clinical trials that have investigated a number of potential therapeutic agents. It looks 
at a range of approaches that have been investigated throughout a number of years 
including stem cell therapy and suggests more innovative ways in tackling the treatment of 
ALS emphasizing on nanotechnology. 
 
Chapter three details the characterisation of the drug amantadine, the biodegradable and 
biocompatible polymers; poly-(D,L)-lactide, three anionic polymethacrylates and two cationic 
polymethacrylates. The aim of the preformulation studies was to determine a suitable 
method to detect amantadine as it lacks a chromophore and conventional methods are 
inefficient. The aim was also to investigate which polymethacrylates in combination with 
poly-D,L-lactide would result in the most stable nanospheres. The techniques used for the 
preformulation studies included; attenuated total reflection Fourier transform infrared 
spectroscopy (ATR-FTIR), thermal and thermodynamic analysis using differential scanning 
calorimetry (DSC), ultraviolet spectroscopy for amantadine detection and Turbiscan 
measurements of the nanoparticles in suspension. The most pertinent formulation was 
observed and further investigations on the particular formulation were carried out in chapter 
four. 
Chapter four presents the details of the formulation of amantadine-loaded ligand-bound 
polymethacrylate-poly-DL-lactide nanospheres using the double emulsion solvent 
evaporation method. A 3 factor Box-Behnken statistical design was employed in the 
optimisation of the preparation of the nanospheres. In the Box-Behnken design; amount of 
polymer, ultrasonication time and total volume of solvent were regarded as the independent 
parameters whereas; particle size, zeta potential, drug entrapment and mean dissolution 
time were considered as dependent responses. Furthermore the optimised nanospheres 
were conjugated to a chelating ligand, diethylenetriamine penta-acetic acid (DTPA) for 
increased cell uptake. Techniques used to verify the distribution and characteristic of the 
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amantadine-loaded DTPA-bound poly-DL-lactide-polymethacrylate (PDLLA-PMA) 
nanospheres include; ATR-FTIR, DSC, Turbiscan® Lab system  and X-ray diffraction. 
 
Chapter five describes the formulation of an N-Vinylcaprolactam ε-caprolactone 
thermosensitive injectable hydrogel. Physicomechanical and physiochemical properties were 
analysed using ATR-FTIR and rheometer. This chapter also looked at the incorporation of 
the amantadine-loaded DTPA-bound nanospheres into the hydrogel and drug release of 
amantadine from the nanosphere-hydrogel composite. 
 
Chapter six describes the in vitro testing of the thermosensitive injectable hydrogel and the 
nanospheres in all of their different forms (i.e. drug-loaded; ligand-bound; placebo) on a 
motor neuron cell line. The uptake of the nanosystems is investigated using fluorescence 
microscopy as well as Cellvizio® imaging system. Toxicity of the different components of the 
system is investigated using MTT assays. 
 
Chapter seven is the conclusions and recommendations component of this dissertation. 
The synopsis of various aspects discussed in the dissertation on ALS treatment and the 
amantadine-loaded DTPA-bound nanospheres embedded in a thermosensitive injectable 
hydrogel is provided. Recommendations for further research on ALS treatment and the 
shortcomings of this study are presented in this chapter. 
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CHAPTER TWO 
A REVIEW OF THERAPEUTIC INTERVENTIONS FOR THE TREATMENT OF 
AMYTROPHIC LATERAL SCLEROSIS 
 
2.1. Introduction 
An unrelenting predicament that has faced physicians and scientist alike is the failure to 
conquer the on-going complexity of treating central nervous system (CNS) disorders. Most 
detrimental of these, are the neurodegenerative disorders that gradually lead to the loss of 
bodily functions and eventually death. Neurodegenerative disorders include, but are not 
limited to, Alzheimer’s disease, Parkinson’s disease, Huntington’s disease and Amyotrophic 
Lateral Sclerosis (ALS). Extensive research has been done in the development of diagnostic 
tools for early detection as well as successful treatment of these disorders. However, very 
modest advancement has been achieved. To date, the blood-brain barrier (BBB) remains 
one of the reasons for the lack of success in the development of treatments as it averts the 
penetration of therapeutic agents and diagnostic tools. There are a few approaches 
imminent in tackling the treatment of neurodegenerative disorders including the use of stem 
cells and antitoxins against mutant forms of the copper and zinc superoxide dismutase 
(SOD1) (Gros-Louis et al., 2010) as well as nanotechnology which require widespread 
innovation.  
In this review, we look at the various theories for the pathophysiology of ALS and some of 
the ways these hypotheses led to the various clinical trials. Numerous ALS clinical trials 
have failed and for the past decade only one drug (riluzole) has been approved by the Food 
and Drug administration (FDA). The approval of only one drug over the years bears 
testimony to the very minimal progress that has been achieved in the treatment of ALS. We 
theorize that some of the unsuccessful therapeutic agents could have prospectively 
produced better results if firstly clinical trials had suitable, effective designs and secondly, if 
innovative drug delivery systems were employed to enhance the bioavailability of potential 
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agents. We then look at studies and lessons from similar disorders that incorporate delivery 
systems to try overcoming the various barriers presented by neurological disorders. 
2.2. The hypotheses surrounding the cause of ALS 
Motor neuron disease (MND) refers to a group of progressive neurodegenerative disorders 
which are distinguished by the deterioration of upper motor neurons and/or lower motor 
neurons (Leigh and Ray-Chaudhuri, 1994). Upper motor neurons have cell bodies located in 
the motor area of the cerebral cortex and have processes connecting with motor nuclei in the 
brainstem or the anterior horn of the spinal cord while lower motor neurons have cell bodies 
located in the brainstem or the spinal cord and have axons innervating skeletal muscle 
fibers. However, MND is commonly used to refer specifically to ALS and is the preferred 
term for this paper.  ALS is characterised by the deterioration of both upper and lower motor 
neurons and presents as spasticity, hyperreflexia, muscle atrophy, fasciculation and 
weakness (Rowland, 1998; Rowland and Shneider, 2001; Nishimura et al., 2004). 
The frequency of ALS ranges between 1.5 and 2.5 in 100 000 (Rojas-Garcia et al., 2012) 
with an average age of onset being between ages 55 and 75 years (Zaldivar et al., 2009). 
The expected survival from the initiation of the symptoms is 3 years (Vance et al., 2009). In 
approximately 90% of the cases, the disease occurs sporadically (Sporadic ALS) whereas 
the remaining 10% are inherited or familial (Familial ALS) (Shaw, 2009). The events 
underlying the disease triggers are completely unknown in ALS which makes developing an 
efficient therapy complicated. Therapies that have been tested for the treatment of ALS 
range from glutamate antagonists, antioxidants, neurotrophic factors, immunomodulatory 
agents, and antiviral agents (Rowland and Shneider, 2001). However, the majority of ALS 
clinical trials have produced unfavourable outcomes, classifying a large number of agents as 
non-beneficial. Many of these clinical trials were discontinued because of the severe side-
effects caused by these particular therapeutic agents, without any improvement in survival. 
Various reasons have been suggested for the failure of these clinical trials. The complexity 
of designing ALS clinical trials and the resulting inconsistent administration of the trials need 
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the most attention. It has been reported that some clinical trials lacked efficient sample sizes, 
while others had contentious duration times as well as ambiguous endpoints (Orrell et al., 
2007), ultimately causing a decrease in statistical significance.  
Mechanisms that are reported to potentially contribute to the neurodegenerative progression 
in ALS include cytoskeletal derangements, oxidative stress and mitochondrial dysfunction, 
protein aggregation, glutamate and excitotoxicity, gene defects, immune dysregulation, and 
growth factor dysregulation amongst others. A few of these mechanisms are discussed 
below: 
 
2.2.1. Oxidative stress and mitochondrial dysfunction 
Jones (2006) described oxidative stress as “a disruption of redox signalling and control” 
whereas Sies (1997) had previously expressed it to be “an imbalance between the oxidants 
and antioxidants in favour of the oxidants, potentially leading to damage”. Figure 2.1 
summarises the reactions that generate reactive oxygen species (ROS) and the 
consequences thereof. The presence of ROS in cells as a result of aerobic metabolism can 
lead to the escape of some electrons from the mitochondrial respiratory chain which in turn 
may result in partial reduction of molecular oxygen during oxidative phosphorylation to finally 
generate hydrogen peroxide (H2O2) and the superoxide radical ion (O2
-) (Barber and Shaw, 
2010). By definition, the reduction of a portion of oxygen forms superoxide. Characterisation 
of calcium-dependent isoforms of nitric oxide synthase has given evidence that suggests 
that ROS can also be produced by the inflammatory activation of neurons (Heneka and 
Feinstein, 2001). Peroxynitrite (ONOO-), a potent oxidant, is produced when superoxide 
reacts with nitric oxide radicals (Squadrito and Pryor, 1998). This highly potent oxidant can 
cause damage to macromolecules, including DNA, thus possibly leading to DNA mutations 
(Marnett, 2000). Enzymes in the body, such as superoxide dismutase, are able to eradicate 
harmful reactive agents and thus neutralise such reactions (Ischiropoulos et al., 1992).  
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Figure 2.1:  Depiction of the sources of reactive oxygen species (ROS) and their targets. 
ROS in cells can lead to the escape of electrons from the mitochondrial respiratory chain 
which may cause partial reduction of molecular oxygen during oxidative phosphorylation 
leading to the production of hydrogen peroxide (H2O2) and the superoxide radical ion (O2
-). 
Oxidative enzymes such as cytochrome P450 in the endoplasmic reticulum, xanthine 
oxidase (XO) and nitric oxide synthase (not depicted) are responsible for the production of 
ROS. Cellular targets attacked by ROS include DNA, proteins, membrane lipids, and 
mitochondria and this attack leads to DNA damage, protein oxidation/ nitration, lipid 
peroxidation and mitochondrial dysfunction respectively (Barber and Shaw, 2010).  
 
 
Several studies have linked oxidative stress in neurons to familial ALS because protein 
carbonyl groups, which are markers of oxidative stress, were detected in ALS post mortem 
tissue (Bowling et al., 1993). In the brain, the inducible form of nitric oxide synthase (NOS) 
has been characterised in microglial cells and its expression described after injury or trauma 
which results in excess nitric oxide (Murphy et al., 1993; Heneka and Feinstein, 2001). Almer 
and co-workers showed the up-regulation of inducible nitric oxide in a transgenic mouse 
model of ALS (Almer et al., 1999). Furthermore, increased levels of 8-hydroxy-2′-
deoxyguanosine (8-OHdG), an indication of oxidative damage to DNA (Alam et al., 1997), 
have been located in motor cortex of sporadic ALS patients (Ferrante et al., 1997). 
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Additionally, 4-hydroxynonenal (HNE), a neurotoxic marker of lipid peroxidation, was found 
in increased quantities in lumbar spinal cord as well as CSF of ALS patients (Pedersen et 
al., 1998; Smith et al., 1998). 
 
2.2.2. Gene defects 
A number of recognized disease-causing mutations have been recorded in FALS families 
(Bedlack et al., 2007). These mutations can be inserted into animals to produce an ALS 
phenotype. Decreasing the assembly of FALS gene products through RNA interference 
(RNAi) technology or antisense oligonucleotides can delay disease progression in animals 
(Bedlack et al., 2007). The ALS-causing mutations that occur in the SOD1 gene are the most 
widespread and best understood. Over 100 various SOD1 point mutations can cause an 
ALS phenotype. These mutations do not appear to result in disease by a loss in function; 
however a toxic gain in function for the mutant SOD1 protein is alleged. More recently, the 
gene encoding a DNA/RNA binding protein FUS/TLS, has been reported to be repeatedly 
mutated in ALS. This mutation results in the cytoplasmic accumulation of mutant FUS 
protein, which is characteristic to ALS pathophysiology (Zhou et al., 2013). It has also been 
reported that a large hexanucleotide repeat expansion positioned within the non-coding 
segment of C9orf72 is the cause of chromosome 9-linked ALS and accounts for 40% of 
FALS (DeJesus-Hemandez et al., 2011; Majounie et al., 2012; Mori et al., 2013). 
 
2.2.3. Protein aggregation 
Superoxide dismutases (SOD) are a group of ubiquitous enzymes capable of catalysing the 
conversion of superoxide anions (Zelko et al., 2002). SOD1 is a copper and zinc homodimer 
(CuZn-SOD) that acts as an antioxidant and is present primarily in the cytoplasm (Green et 
al., 2002; Zelko et al., 2002). One of the hypotheses of ALS is that a mutation in this enzyme 
results in neurotoxicity, and is considered to be as a result of a gain in function (Watanabe et 
al., 2001).  
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Figure 2.2: SOD1-immunoreactive aggregates that have formed in: A) transgenic mice 
expressing FALS-linked mutations in the SOD1protein. Hemotoxylin and eosin (H&E) 
staining was used to detect aggregates in the ventral portion of a spinal cord from an end-
stage mouse expressing mutant SOD1. The figure shows an inclusion that reveals a halo of 
intense immunoreactivity to SOD1 antibodies (Bruijn et al., 1998). B) anterior horn cells in 
FALS patients observed on H&E also showing immunoreactivity to SOD1 antibodies 
(Okamoto et al, 2011). 
 
There are evidently 100 single point mutations of SOD1 that result in the familial type of ALS 
(Banci et al., 2008). Familial ALS promotes the formation of cytoplasmic mutant SOD1 
aggregates found in motor neurons (Vance et al., 2009), (Figure 2.2) but the factors leading 
to this aggregation are still elusive. However, metallation of SOD1 proteins is suggested to 
play an important role in reducing the propensity of these proteins to aggregate (Banci et al., 
2008). Conversely, the 43kDa TAR-DNA-binding protein (TDP-43) has been identified as the 
key component of ubiquinated protein aggregates found in many patients with sporadic ALS 
and (SOD1)-negative FALS (Yokoseki et al., 2008). The irregular molecular weight 
fragments of TDP-43 have been found in affected neurons suggesting that this protein is 
involved in the pathophysiology of SALS, although the pathogenesis is uncertain (Yokoseki 
et al., 2008). Furthermore, there have been demonstrations showing that the pathological 
forms of TDP-43 are ubiquinated and hyperphosphorylated and show a loss of the normal 
nuclear TDP-43 staining in cells harbouring neuronal cytoplasmic inclusions (Mackenzie et 
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al., 2007). This evidence shows that TDP-43 is the major pathological protein in sporadic 
ALS. 
 
2.2.4. Glutamate and excitotoxicity 
The irregular stimulation of glutamate receptors (GluRs) results in excitotoxic injuries leading 
to highly increased levels of calcium entering into neurons (Foran and Trotti, 2009). This 
process is proposed to be one of the theories of the pathophysiological mechanisms of both 
types of ALS. It is has been found  that motor neurons have a high concentration of GluRs, 
and are the most susceptible neurons to excitotoxicity caused by influx of Ca2+  through  
GluRs (Le Verche et al., 2011). GluR2 subunit expression and editing results in Ca2+ 
impermeability to the AMPA GluRs which mediate fast excitatory transmission. In ALS, 
however, there is reduced GluR2 RNA editing at the glutamine/ arginine (Q/R) site which 
causes Ca2+ permeability at the GluR2 (Q)-containing AMPA receptors (Heath and Shaw, 
2002; Le Verche et al., 2011). In vitro studies have shown that an increase in glutamate 
levels and the over-stimulation of NMDA receptors lead to motor neuron death (Urushitani et 
al., 2001). Additionally, an increase in calcium influx in motor neurons through activation of 
AMPA receptors containing an unedited GluR2 subunit demonstrated an analogous effect 
(Vandenberghe et al., 2000). Furthermore, cerebrospinal fluid retrieved from ALS patients 
caused excitotoxicity in neuronal cultures, which was not evident in healthy controls (Cid et 
al., 2003). A decrease of glutamate transport in ALS has also been observed, which is 
evidently caused by the loss of EAAT2 protein (a high affinity glutamate or excitatory amino 
acid transporter) in the spinal cord and motor cortex of ALS patients (Guo et al., 2003; Le 
Verche et al., 2011). EAAT2’s main function is to keep extracellular glutamate at levels that 
are suitable for both neurotransmission and neuronal survival. EAAT2 has been described 
as not having a primary role in the degeneration of motor neurons but rather a contributive 
role. This contributive role was shown in a study designed to increase EAAT2 through over-
expression in ALS SOD1 mice, where a 2-fold expression of EAAT2 amplified glutamate 
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uptake by 2-fold, delayed symptom onset (by 17%) and motor neuron death, with negligent 
effects on the inception of paralysis, weight loss or life span (Le Verche et al., 2011). 
 
2.2.5. Growth factor dysregulation  
Defective neurotrophic factor coordination has been proposed as a primary or secondary 
cause for the loss of motor neurons seen in ALS (Ekestern, 2004). The theory is based on 
the fact that the administration of neurotrophic factors to rat ALS models presented with 
neuroprotective effects (Corse et al., 1999). In a study by Corse and co-workers (1999) on 
spinal cord cultures from postnatal rats, insulin-like growth factor-I (IGF-I), glial cell-line 
derived neurotrophic factor (GDNF), and NT-4/5 were shown to have highly neuroprotective 
properties. Comparably, brain-derived neurotrophic factor (BDNF), ciliary neurotrophic factor 
(CNTF), and NT-3 exhibited no notable outcome. An additional neurotrophic factor that has 
been investigated is vascular endothelial growth factor (VEGF), which has shown to 
encourage motor neuron survival in animals. ALS patients have been reported to have 
considerably decreased plasma levels of VEGF, which is distinct from previously mentioned 
growth factors (Ekestern, 2004). In an interesting in vivo study by Storkebaum and co-
workers (2005), VEGF delayed onset of paralysis by 17 days, improved motor performance 
and prolonged survival by 22 days in a rat model of ALS. Overall, ALS patients have, 
however, not experienced significant benefits from treatment with neurotrophic factors. The 
lack of positive results may be due to the fact that in vivo studies have been performed 
mostly on rat models of FALS while most ALS patients have the sporadic version.   
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2.3. Drug Formulations in ALS Clinical Trials 
These various aforementioned theories formed the premises of the many clinical trials that 
ensued. The oxidative stress theory led to clinical trials that investigated anti-oxidants such 
as acetylcysteine, selegiline, creatine, selenium as well as coenzyme Q10. In a 
representative study to establish whether vitamin E (α-tocopherol), with well-known anti-
oxidant properties, would be efficient in treating ALS, it was concluded that vitamin E had no 
effect on the survival and motor function of ALS patients (Desnuelle et al., 2001). A phase II 
study testing coenzyme Q10 (CoQ10) was completed in 2008 and it was concluded that 
2 700mg of CoQ10 daily for 9 months produced results that were not satisfactory enough to 
continue to phase III studies (Kaufmann et al., 2009). Similar conclusions were reached with 
all the other anti-oxidant therapeutic agents. 
 
As mentioned earlier, neurotrophic factors have also been tested to tackle the growth factor 
dysregulation theory. The brain-derived neurotrophic factor (Ochs et al., 2000), insulin-like 
growth factor 1 (Sorenson et al., 2008), ciliary neurotrophic factor (Miller et al., 1996), and 
thyrotropin-releasing hormone (Brooke et al., 1986) have all produced negative outcomes in 
ALS clinical trials. In two randomized, double-blind, placebo-controlled, multi-centre, multi-
national clinical trials investigating Xaliproden (a small non-peptide composite that has the 
potential of promoting the release of neurotrophic factors), minimal success was observed 
(Meininger et al., 2004). Vascular endothelial growth factor (VEGF) is a protein found in the 
body that plays a fundamental role in angiogenesis and the survival of motor neurons 
(Zinman and Cudkowicz, 2011). Patients with FALS and SALS have been reported to have 
considerably decreased levels of this protein leading to cause motor neuron death (Van Den 
Bosch et al., 2004). Phase I and II studies are still in progress to further investigate 
intracerebroventricular administration of VEGF in patients with ALS using an implanted 
catheter and SynchroMed® II Pump (An open label, safety and tolerability continuation study 
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of intracerebroventricular administration of sNN0029 to patients with amyotrophic lateral 
sclerosis, 2013). 
Minocycline is an antibiotic that inhibits apoptosis and also has anti-inflammatory effects 
(Bernardino et al., 2009). Moreover, minocycline has shown to have neuroprotective 
properties in neurodegenerative disorders (Tikka et al., 2001). This knowledge prompted a 
study to assess the efficacy of minocycline in ALS patients as a way to tackle the apoptosis 
theory in the pathophysiology of ALS. Although results from animal models were positive, 
studies did not translate into positive results in human ALS (Gordon et al., 2007). 
 
Clinical trials employing the anti-glutaminergic approach i.e lamotrigine, dextromethorphan, 
gabapentin and branched amino acids were all found to be non-effective. However, riluzole, 
also a glutamate antagonist, became the only drug that received approval by the Food and 
Drug Administration for the treatment of ALS (Cheah et al., 2010; Bellingham, 2011). It is a 
glutaminergic transmission modulator which inhibits the release of glutamate at the 
presynapsis (Lamanauskas and Nistri, 2008). It also non-competitively inhibits the action of 
excitatory amino acids postsynaptically (Samuel et al., 1992). Riluzole has further 
mechanisms of action including the inactivation of voltage-gated sodium channels and 
activation of G-protein-dependent processes (Iłżecka et al., 2003). 
 
In a study by Bensimon and co-workers (1994), survival rate was the primary end point and 
it proved to be considerably improved with the use of riluzole in ALS patients. The study 
showed that riluzole had greater effects in patients with ALS of bulbar onset than those of 
limb onset and that there is a therapeutic dependence on site of onset of disease for a larger 
and substantial effect of riluzole. Treatment with riluzole showed major therapeutic effects 
over the first 12 months of use and a decline thereafter ensued. An enhanced and infinite 
way of treating ALS and similar neurodegenerative disorders is therefore needed in order to 
achieve improved results.  
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More than 30 therapeutic agents have been tested for their efficacy and effectiveness in 
ALS. However, countless trials have been negative and researchers are now focusing on 
ways to improve clinical trials and identify new medications for ALS. A major emphasis of 
research is now to discover biomarkers which would enable earlier diagnosis of ALS (which 
currently takes more than a year on average) and optimistically result in future therapies 
being more effective early in the course of the disease (Wagner, 2009). Trialists also 
understand that there is a need to uncover a method to measure the effect of a drug (akin to 
viral count in trials of HIV). Previously, trialists detected a large size effect to save costs 
when testing a new agent and therefore aimed for at least a 30% difference from placebo 
(Mitsumoto et al., 2004). Currently trial designs aim to lower the effect size and look for 
effects of perhaps only 10% to 20% which includes drugs that have a modest impact on the 
disorder (Mitsumoto et al., 2004). Moreover, a few methods have been suggested to 
minimise missing data in clinical trials and there has been emphasis on early trial phase 
trials to select dose (Mitsumoto et al., 2004; Fleming, 2011; Dziura et al., 2013). Many phase 
III trials may have failed because of inadequate definition of dose and pharmacodynamics 
markers in animal and early phase human trials (Levy et al., 2006). Selecting dose is done in 
sequence where pharmacokinetics and safety of different doses are tested in phase I 
following investigations in the laboratory. Phase II follows with in-depth safety, biological 
effect and dose selection and lastly phase III with efficacy (Mitsumoto et al., 2004). Trialists 
are also looking to address the issue of using animal models as predictors of therapeutic 
agents’ effects in human studies. The accuracy of using the SOD1 transgenic mouse model 
to extrapolate data for human sporadic ALS is questioned as trialists have limited experience 
in ALS trials and there is uncertainty whether human ALS and ALS in mouse models are 
truly representations of each other (Suzuki et al., 2012).  Attending to these issues will surely 
lead to better therapies following the discovery of causes.  
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The failure of these therapeutic agents can perhaps furthermore be attributed to the 
challenges that these agents encounter in reaching their target site. The BBB has brought 
forth major obstacles for the development of therapeutic agents targeting the central nervous 
system. It obstructs the passage of xenobiotic molecules to the brain thus making the 
penetration of these agents to their target sites difficult. It is highly expected for this, together 
with the issues experienced in clinical trials to be amongst the factors in the lack of efficacy 
of these agents. As a result of the hindrance by the BBB, the bioavailability of most of these 
agents is very low. Furthermore, gastric absorption of some of these agents is highly 
reduced and the increase in dosage of therapeutic agents in an attempt to overcome this 
reduction is often counteractive (Amsterdam, 2003; Rais et al., 2011). Increased doses may 
lead to saturation of transporter uptake in the intestine. Gabapentin for example has a 
bioavailability of 60% but this can decrease to almost 35% with increasing dosage (Rais et 
al., 2011). Selegiline also has difficulty in being taken up by the intestine, with a 
bioavailability of only 4%. A Selegiline Transdermal System, however, has been used to 
increase the bioavailability up to 74% (Amsterdam, 2003). This increase in bioavailability 
enhances the chances of this agent to reach its target site in the brain. The application of 
delivery systems that will drastically alter the bioavailability of therapeutic agents, through 
increased gastric absorption and most crucially by manipulating the BBB is an aspect that 
needs extensive research.  
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2.4. Intricacies and Prospects for Formulation Success Across the Blood-Brain 
Barrier in ALS Therapy 
The BBB is relatively impermeable to various molecules such as proteins, small peptides 
and amino acids (Gabathuler, 2010). Small lipophilic molecules are able to pass easily from 
blood capillaries via passive diffusion (Jolliet-Riant and Tillement, 1999), whereas larger 
charged molecules require some form of aid, for instance gated channels (Roney et al., 
2005). This rigid control of the passage of molecules is maintained by the brain capillaries 
which are made up of endothelial cells that have exceedingly tight junctions with extremely 
high electrical resistance (Rubin et al., 1991). Molecules moving across the BBB do so in a 
unidirectional manner. This movement is dependent on the concentration of the molecules 
and occurs from the plasma to the brain or vice versa (Ma et al., 2005). The difference 
between the two unidirectional flow rates provides the net flux. This net flux establishes the 
therapeutic concentrations achieved by drugs targeting the CNS (Modi et al., 2010). To 
bypass the BBB, drug delivery approaches include osmotic disruption of the BBB using 
hyperosmolar agents, Trojan horse receptor mediated transport, nasal drug delivery, 
receptor-mediated transport, active efflux, carrier-mediated transport, and transcranial 
delivery (see Figure 2.3). 
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Figure 2.3: Mechanisms for drug delivery to the brain: A) osmotic disruption of the BBB. A 
hyperosmolar agent (e.g. mannitol) is introduced to the endothelial cells of the BBB which results in 
temporary shrinkage of the cells, allowing therapeutic agents to pass through to the brain and reach 
their target site. BBB disruption is able to increase drug delivery to the brain by up to 50-100 fold 
(Siegal et al., 2000; Angelov et al., 2009); B) trojan horse receptor mediated transport. A receptor-
specific monoclonal antibody (mAb) referred to as a BBB molecular Trojan horse, is fused to a non-
transportable drug. The Trojan horse binds a specific receptor on the BBB and this enables transport 
across the BBB. The drug can then bind its particular receptor, on brain cells to trigger the desired 
pharmaceutical effect in the brain (Pardridge, 2006); C) nasal drug delivery. Drugs are able to reach 
the CNS from the nasal cavity by a direct transport across the olfactory region located at the roof of 
the nasal cavity. It is the only site in the human body where the nervous system is in direct contact 
with the surrounding environment. The drug can cross the olfactory epithelium by a transcellular route 
through the cells and/ or a paracellular route between the cells. The drug can also be transported 
through the olfactory neuron cells by intracellular axonal transport mainly to the olfactory bulbs (Illum, 
2003); D) active efflux. ATP-binding cassette (ABC) transporters such as P-glycoprotein (Pgp), 
multidrug resistance protein (MRP1-6), and breast cancer resistance protein (BCRP) are membrane 
proteins situated at the luminal site of brain capillary endothelial cells that form the BBB. These 
transporters use the energy of ATP hydrolysis to translocate solutes across cellular membranes. They 
are effective as efflux pumps and drug transporters and are a target for alteration of the BBB for entry 
of therapeutic drugs into the brain (Loscher and Potschka, 2005); E) carrier-mediated transport. 
Therapeutic agents that have low lipid solubility are able to pass through the BBB via transport 
proteins. Drugs are designed so they can be transported into the brain via various transport systems 
such as the hexose transport systems, amino acid transport systems, monocarboxylic acid transport 
systems and amine transport systems (Tsuji and Tamai, 1999).  
However, it has been reported that the BBB as well as the blood-spinal cord barrier (BSCB) 
are altered in ALS patients (Garbuzova-Davis and Sanberg, 2014; Nicaise et al., 2009). This 
alteration is evident in endothelial cell degeneration, capillary leakage, perivascular oedema, 
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down-regulation of tight junction proteins, and micro-haemorrhages (Garbuzova-Davis and 
Sanberg, 2014). Deterioration of endothelial and pericyte cells, which results in 
compromised vascular barrier integrity in the brain and spinal cord in ALS patients, may 
possibly be a significant impediment for successful drug delivery to the CNS. An 
accumulation of basement membrane collagen from the damaged barriers also modifies 
barrier influx and efflux transport systems which leads to a decrease in nutritional agents 
being transported to the brain and an increase in metabolites. In addition, augmentation of 
P-glycoprotein (P-gp) and the breast cancer resistance protein (BCRP) were determined in 
brain and spinal cord micro-vessels in both SOD1 animal models and ALS patients. It is 
suggested that the impairment of these P-gp and BCRP efflux transporters may encourage 
an obstruction of therapeutic agents in ALS (Jablonski et al., 2012). Overall, most drug 
delivery mechanisms rely on an intact BBB, which unsurprisingly presents a vast 
complication for drug discovery in ALS. It is important, therefore, to consider the implications 
that a damaged BBB and BSCB exhibit when developing a treatment for ALS. 
2.5. Specialized Therapeutic Agent Delivery Systems: A Possible Solution 
2.5.1. Delivery systems for gene therapy 
There have been prospects in using gene therapy in the treatment of ALS where 
neurotrophic factors have shown potential in preventing the degeneration of motorneurons in 
culture and in vivo, after peripheral nerve injury. Systemic administration of neurotrophic 
factors, however, limits their efficacy. Several studies have reported incorporating biological 
components as carriers for these neurotrophic factors (Table 2.1). A combination therapy of 
glial cell line derived neurotrophic factor (GDNF) and human mesenchymal stem cells 
(hMSC) was investigated in a rat model of familial ALS by Suzuki and co-workers (2008). 
hMSC are mostly isolated from bone marrow tissue, although they are also found in other 
mesenchymal tissues (Aggarwal and Pittenger, 2005). They have shown neuroprotective 
effects and the ability to release cytokines as well as other growth factors which are believed 
to save cells from continuous neurodegeneration (Cova et al., 2012). Suzuki and co-workers 
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(2008) further demonstrated that the combination of the therapeutic effects of hMSC 
transplants and GDNF administration results in increased motor neuron survival as well as 
function in a rat model familial ALS model. In this way, the hMSC were used as a delivery 
system for the GDNF in the skeletal muscle thus evading the need for host cells to provide 
the growth factors while enduring neurodegeneration thereby increasing the overall lifespan 
of the rats by up to 28 days. 
In a similar study, human neural progenitor cells (hNPC) were used as carriers for GDNF in 
rats (Klein et al., 2005). The hNPC differentiated into astrocytes and neurons after 
incorporation into the nervous system and restored the damaged neurons. New astrocytes 
repaired the extracellular environment of motor neurons and aided in their regular function. 
The hNPC survived for up to 11 weeks after implantation into the lumbar spinal cord of rat 
ALS model where they released GDNF (Klein et al., 2005). 
Mohajeri and co-workers (1999) prepared primary myoblasts from skeletal muscles of infant 
mice and infected them with retroviral vectors. These retroviral vectors contained within them 
either GDNF or β-galactosidase. The myoblasts were then implanted into the hindlimbs of a 
transgenic mouse model of ALS before the onset of symptoms or motor neuron 
degeneration. Later, the tracer fluorogold was injected into the same muscles in order to 
determine the number and size of the motor neurons that were not damaged as well as the 
number of motor neurons that preserved axonal projections to the treated muscles. This 
study showed that GDNF-secreting myoblasts protected the motor neurons in these muscles 
from degeneration, enhanced their motor function, and delayed the onset of symptoms. In a 
phase I study, encapsulated genetically modified xenogeneic cells were used to transport 
ciliary neurotrophic factor (CNTF) in ALS patients (Aebischer et al., 1996). Systemic delivery 
of CNTF caused many undesirable side effects and thus clinical trials were discontinued. 
This delivery system was implanted in the patients’ lumbar intrathecal space where CNTF 
was released without the drawback of side effects observed in systemic delivery (Aebischer 
et al., 1996). A similar delivery system was developed for human retinal degeneration and 
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tested in a phase I trial. Cells transfected with the human CNTF gene were encapsulated 
and surgically implanted into the vitreous of the eye (Sieving et al., 2006). In an in vitro study 
for controlled release and sustained delivery of CNTF, nanospheres and microspheres were 
used to optimise CNTF encapsulation and release (Nkansah et al., 2008). 
Table 2.1: Outline of stem cell transportation in Motor Neuron Disease. Adapted from Gowing and 
Svendsen (2009) 
Model Cell-Type 
Grafted 
Method of 
Administration 
Effect on  
Pathology 
Mechanism 
 
C7-C8 ventral root 
avulsion rat 
 
Spinal rat 
npc
GFP
 
 
Intraspinal 
 
4.1-fold ↑ MN 
Survival 
 
Trophic support 
 
SOD1
G93A 
rat 
 
Rat NSC 
 
Tail vein injection 
 
Not investigated 
 
Not investigated 
 
SOD1
G93A 
rat 
 
hNPC
GDNF
 
 
Intraspinal 
 
↔ Lifespan approx. 
2-fold ↑ MN survival 
 
Trophic support 
 
SOD1
G93A 
mice 
 
hNSC
VEGF
 
 
Intrathecal (L5-L6) 
 
1.1-fold ↑ Lifespan 
 
↓ apoptosis, 
trophic support 
 
SOD1
G93A 
rat 
 
Spinal hNSC 
 
Intraspinal 
 
Not investigated 
 
Not investigated 
 
SOD1
G93A 
rat 
 
Spinal hNSC 
 
Intraspinal 
 
Delayed onset by 
1.08-fold  
1.12-fold ↑ lifespan 
 
Not investigated 
 
SOD1
G93A 
mice 
 
hNPC
BDNF
, 
IGF-1, 
GDNF 
or VEGF 
 
Cisterna magna or 
lateral ventricles 
 
1.27-fold ↑ MN 
survival 
 -GDNF ♂ 
1.08-fold ↓ survival- 
GDNF ♀ 
 
Not investigated 
 
SOD1
G93A 
mice 
 
hMSC 
 
Irradiation and tail 
vein injection 
 
Delayed onset 
1.1-fold ↑ lifespan 
1.45-fold ↑ MN 
survival 
 
Not investigated 
 
SOD1
Leu26de1TT 
mice 
 
Rat MSC 
GFP
 
 
Fourth ventricle 
 
No effect 
 
N/A 
 
SOD1
G93A 
rat 
 
Rat MSC 
 
 
Intrathecal 
 
1.13-fold ↑ lifespan 
1.71-fold ↑ MN 
survival 
 
↓ microgliosis, 
 ↓ inflammation 
 
SOD1
G93A 
mice 
 
hMSC 
 
Intraspinal 
 
1.06-fold ↑ MN 
survival ♀ 
motor behavior 
 
 
↓ microgliosis 
↓astrocytosis 
hMSC = human Mesenchymal stem cells; GFP = glial fibrillary protein; MSC = Mesenchymal stem 
cells; IGF-1 Insulin-like growth factor-1; GDNF =  glial cell line-derived neurotrophic factor; BDNF = 
brain derived neurotrophic factor; MN = motor neuron; hNPC = human neural progenitor cells; NSCs 
= neural stem cells; SOD1 = superoxide dismutase 1; VEGF = Vascular endothelial growth factor 
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2.5.2. Nano-drug delivery systems: Structure and functional properties 
According to the U.S. National Nanotechnology Initiative (NNI), nanotechnology is “the ability 
to understand, control and manipulate matter at the level of individual atoms and 
molecules…in order to create materials, devices, and systems with fundamentally new 
properties and functions because of their small structure” (Roco et al., 2007). Using this 
knowledge it is possible to control the primary elements of this technology and incorporate 
them into biological systems. Polymeric resources are used to formulate structures on a 
nanometer scale capable of interaction with biological structures at a molecular level. 
Continuous research of these nano-structures could be beneficial in treating CNS diseases 
that have presented complicated challenges such as decreased bioavailability of therapeutic 
agents. 
There are various nano-sized particles that have been formulated for biomedical 
applications; each with different physicochemical properties. These nano-sized particles are 
able to by-pass the BBB and carry out their required therapeutic or diagnostic functions. 
Systemically delivered nanoparticles cross the BBB via either receptor-mediated 
transcytosis, which necessitates the attachment of specific ligands on the nanoparticle 
surface, or adsorptive-mediated transcytosis, which employs charge-based interactions 
(figure 2.4a). Moreover, nanoparticles coated with polysorbate T-80 have shown to mediate 
the endocytosis of drugs across the BBB through the interaction polysorbate T-80 has with 
brain micro-vessel endothelial cells (figure 2.4b) (Sun et al., 2004; Tian et al., 2011). 
Polysorbate 80-coated nanospheres adsorb apolipoprotein E (ApoE) from blood plasma and 
imitate low density lipoprotein, having particular receptors at the surface of endothelial cells 
of the BBB. The therapeutic agent may then be released into these cells from the 
nanospheres and diffuse into the brain, or the particles may be transcytosed. Other 
processes such as tight junction modulation or P glycoprotein inhibition may also occur.  
Polysorbate T-80 therefore plays a role in brain targeting, which improves the transporting 
properties of the nanospheres and gives them an added advantage. The appeal of 
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nanoparticles is further enhanced by their biodegradability and biocompatibility 
characteristics. Additionally, it is possible to insert nanoparticles into a biodegradable 
polymeric biomaterial (hydrogel) to form a dual drug delivery system (Gong et al., 2012). 
Hydrogels have been developed to be utilised in the treatment of CNS disorder (Lee et al., 
2006), however, in combination with nanoparticles the functions of both the nanoparticles 
and the hydrogel could be enhanced.  
 
Figure 2.4: A) Nanoparticles that are delivered systemically cross the BBB via either 
receptor-mediated transcytosis, which requires the presence of specific ligands on the 
nanoparticle surface, or adsorptive-mediated transcytosis, which utilizes charge-based 
interactions. B) An innovative mode of drug delivery to the brain using polysorbate 80-coated 
nanospheres. Polysorbate 80-coated nanospheres adsorb apolipoprotein E (ApoE) (1) from 
blood plasma and emulate low density lipoprotein, having particular receptors at the surface 
of endothelial cells of the BBB. The drug may then be released into these cells from the 
nanospheres and diffuse into the brain (2), or the particles may be transcytosed (3). Other 
processes such as tight junction modulation or P glycoprotein inhibition may also occur (4) 
(Radhika et al., 2011). Adapted from Vauthier et al., 2003. 
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There are several nano-sized drug delivery systems that have been developed for 
Alzheimer’s disease and Parkinson’s disease but few have been explored for the treatment 
of Huntington’s disease and ALS. These drug delivery systems are discussed in more detail 
further down in this paper. ALS though not as common as AD or PD is as damaging to 
neurons with eventual limb paralysis, loss of speech, swallowing and breathing functions and 
ultimately death (Mitchell and Borasio, 2007).  
Nanotechnological delivery systems have great significance in the development of 
therapeutics approaches because they can modify the pharmacological profiles of drugs and 
related therapeutic properties (Prokop and Davidson, 2008) by allowing a more predictable 
control of drug release kinetics among other things.  These systems can achieve targeted 
drug delivery, where the drug remains in its active conformation, and additionally, achieve a 
positive alteration in the pharmacokinetics, pharmacodynamics and, biodistribution of the 
drug (Craparo et al., 2011). These nano-sized delivery systems have been designed in 
various geomatries, configurations and surfaces ranging from nanofibers to polymeric 
nanomicelles as shown in table 2.2.  
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Table 2.2: The various structural designs of nanosystems for possible application in ALS drug therapy 
Nanosystem Description 
Nanoliposomes 
 
TEM micrographs of nanoliposomes (Imran et al., 2012)  
 
 
Nanoliposomes are lipid layer/s surrounding an 
aqueous core. They can be used to deliver both 
hydrophilic (aqueous layer) or hydrophobic (lipid layer) 
drugs. Nanoliposomes are prepared by sonicating 
phospholipids in water (Zaru et al., 2011). 
 
Nanofibers 
  
a) and b) SEM images of hollow nanofibers;  
c) TEM image and d) selected area electron 
diffraction (SAED) patterns of nanofibers (Li et al., 2013) 
 
 
These are fibers that are minimized to nanometers (e.g. 
10×10
_3
–100×10
_3
 mm) and are fabricated by drawing, 
template synthesis, phase separation, self-assembly, 
electrospinning, etc (Huang et al., 2003). 
Nanobubbles 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
In vitro ultrasonic images of Nanobubbles at  
high frequency diagnostic ultrasound in contrast  
pulse sequencing mode (Yin et al., 2012). 
 
 
 
Nanobubbles are nano-scopic soft domains at the 
liquid-solid interface that resemble spherical caps with 
heights of ~10nm and diameters of 2R ~ 100nm. They 
correspond to a small contact angle of θ ~ 10º. In other 
words, they are nano-scale gas bubbles located at the 
liquid-solid interface (Brenner and Lohse, 2008). 
Nanogels 
  
Polymer precursor and emulsion methods 
for nanogel synthesis (Chacko et al., 2012). 
 
 
 
 
 
 
These are networks of cross-linked nanoparticles that 
consist of ionic and non-ionic polymeric chains 
prepared using an emulsification solvent. They are able 
to swell in water as well as integrate drugs (Modi et al., 
2010). 
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Nanocrystals 
 
HRTEM image showing CdSe nanocrystals (Talapin et al., 2001). 
 
 
These are nanoparticles with a crystalline character. 
They can be used as drug nanocrystals where the drug 
makes up the entire nanocrystal instead of having a 
carrier. Nanocrystals can also be used as 
semiconductors and utilized as probes to allow for 
imaging and diagnostics (Parak et al., 2003). 
 
Nanomicelles 
  
 
Nanomicelle displaying a hydrophobic inner  
and hydrophilic outer layer (Kim et al., 2008). 
 
 
 
These are formed from amphiphilic block copolymers 
consisting of hydrophilic and hydrophobic portions 
(Hyun et al., 2008). 
 
 
 
2.6. Lessons learned from nanotechnology in other neurodegenerative disorders 
There are several more examples of nanotechnology being employed in testing of potential 
new treatments in neurodegenerative disorders like Alzheimer’s disease and Parkinson’s 
disease than there are for ALS (Table 2.3). We can take lessons from the advances in these 
disorders and extrapolate them to ALS. Below are certain examples that can be employed in 
investigating ALS treatment because the delivery systems developed look at aspects of the 
disorder that are also found in ALS and can therefore be beneficial in finding efficient 
treatment in ALS. It is important, however, to note that the advances taken in these 
neurodegenerative disorders are still groundwork. More testing needs to be done to be 
certain of the actual potential these drug delivery systems possess for ALS patients. 
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2.6.1. Examples of nanotechnological approaches employed in Alzheimer’s disease 
2.6.1.1. Gold nanoparticles for the detection of Alzheimer’s disease biomarker 
Based on the fact that there is currently no absolute cure for Alzheimer’s disease, detection 
of the disease is vital in its very early stages. Early detection will enable the treatments 
already in the market to work more efficiently and effectively. Tau protein is found in the 
cerebrospinal fluid (CSF) and is hyperphosphorylated in patients with AD (Neely et al., 
2009). Neely and co-workers (2009) demonstrated a label-free, fast and highly sensitive 
monoclonal anti-tau anti-body (tau-mab) coated gold nanoparticle based two-photon 
Rayleigh scattering (TPRS) assay for the selective detection of Alzheimer’s tau protein in a 1 
pg/mL level. It was shown that TPRS is highly sensitive to tau protein (2 magnitudes more 
sensitive than the conventional colorimetric method) and is able to differentiate between the 
tau protein and other proteins present in the CSF. The TPRS targets the early stages of AD 
and is easy and fast, making it a promising tool for diagnosing Alzheimer’s disease. 
Gold nanoparticles were also used in an in vitro study to disrupt the growth of β-amyloid 
fibrils and plaques that play a crucial role in mental dysfunction. Gold particles were attached 
to β-amyloid targets and microwave fields were applied, a procedure that allowed a selective 
supply of energy to dissolve and separate the aggregates. After 7 days of incubation at 37ºC 
the sample was observed for precipitation and no aggregates had formed. The treatment 
thus showed that it successfully separates the fibrils and decreases the propensity for the β-
amyloid proteins to reaggregate (Kogan et al., 2006). Although this was only an in vitro 
study, these gold nanoparticles could possibly be employed in developing a system that 
could manage the aggregation of the mutant proteins in ALS. 
2.6.1.2. Cerium oxide nanoparticles 
Cerium oxide nanoparticles have long lasting anti-oxidant properties which makes them a 
useful tool for the treatment of neurodegenerative disorders caused by oxidative stress. Both 
Alzheimer’s disease and ALS have oxidative stress as a theory for pathophysiology.  
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Cerium oxide has the ability to transfer and absorb oxygen atoms, oxidise unsaturated 
hydrocarbons and transfer electrons to hydrocarbon radicals (Singh et al., 2007). Singh and 
co-workers (2007) treated mixed cultures of cortical brain cells with 10nm cerium oxide 
particles and this resulted in an increased life span of the cells by up to six fold. This in vitro, 
it was shown that using electron paramagnetic resonance that cerium oxide nanoparticles 
did not produce free radicals and were exceptional scavengers of both superoxide and 
hydroxyl radicals. Oxidative stress has also been linked to alterations of glutathione (GSH) 
metabolism resulting in reduced GSH levels in the brain. GSH delivery to the brain faces the 
same restriction other agents have and therefore methods to transport it across the BBB 
have been developed. GSH has been encapsulated in liposomes as well as lipid vesicles 
made of lecithin and glycerol where the latter formulation was tested on mixed 
mesencephalic cultures treated with paraquat and maneb in an in vitro study (Cacciatore et 
al., 2012). The liposomal GSH was taken up into neurons, hydrolysed and the amino acids 
comprising GSH were released from lysosomes and used for GSH biosynthesis which later 
demonstrated neuroprotection. Other nanocarrier systems for GSH include nanoparticles 
coated with hydrophilic polymers such as polyethylene glycol or polysaccharides such as 
chitosan, pectin, hyaluronic acid and dextran However, a recent in vitro study by Brasil and 
co-workers (2013) showed that GSH may be involved in the activation of FALS-linked 
mutant SOD1 during chronological aging.125 GSH therefore may not be a suitable 
therapeutic agent in ALS.  
2.6.2. Nanotechnologies employed in Parkinson’s disease  
2.6.2.1. Biodegradable nanofibers in stem cell therapy 
A combination of stem cell therapy and polymer-based nanotechnology has been and 
continues to be tested as a potential future therapy in PD. Biodegradable scaffolds that can 
promote restoration of damaged neurons by stem cells were developed using chemicals and 
electrospinning (Nisbet et al., 2008; Modi et al., 2010). This process allowed for the 
modification of the arrangement of nanofibers to form scaffolds that can be incorporated into 
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the body (Nisbet et al., 2008). The scaffolds can then be infused into the body and stem cells 
integrated accordingly. There are various types of scaffolds that can be used for neuron 
damage repair and the preference of type of materials used is subjected to the cellular 
reaction to materials. This reaction depends on the physical and chemical properties of the 
materials and the application for which the scaffolds are employed (Nisbet et al., 2008). 
Neuron damage is common to all neurodegenerative disorders therefore these scaffolds 
could potentially be used in the development of new therapies in ALS. 
2.6.2.2. Nanoparticles modified with Odorranalectin 
Intranasal delivery, as a way to bypass the BBB has long been investigated and there has 
been a need to improve the drug absorption from the nose to the brain by increasing the 
resident time of drugs in the nasal cavity. The enhancement of drug absorption can be 
achieved by introducing bioadhesive compounds, such as lectins, to drug delivery systems 
in order to target the nasal mucosa and increase absorption at that site. Odorranalectin (OL), 
the smallest lectin with decreased immunogenicity when compared with the other lectins, 
was attached to nanoparticles for the advancement of drug delivery to the brain via the nasal 
route (Wen et al., 2011).  
The nanoparticles were formulated using poly (ethylene glycol) and poly (lactic-co-glycolic 
acid). In this study, hemiparkinsonian rats were given urocortin (UCN) loaded OL-
nanoparticles by means of intranasal administration. Rotation behaviour tests, 
neurotransmitter determination and tyrosinehydroxylase tests were performed. Results 
indicated that the uptake of the nanoparticles was increased by modification with OL and 
therapeutic effects of UCN were improved in hemiparkinsonian rats. Such a system could 
potentially be used in the development of new therapies in ALS by incorporating riluzole, or 
any other promising therapeutic agents that have been researched but have failed to 
produce desired results. 
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2.6.2.3. Lactoferrin-coupled PEG-PLGA nanoparticles 
Lactoferrin (Lf), a cationic iron-binding glycoprotein (Naot et al., 2005; Hu et al., 2011), was 
used to enhance polyethylene glycol-polylactide-polyglycolide (PEG-PLGA) nanoparticles for 
delivery of therapeutic agents across the BBB (Hu et al., 2011). Lf receptor is found on the 
BBB and transports Lf across the BBB. Following its thiolation, Lf was attached to the 
maleimide function enclosing the PEG incorporated nanoparticle thus producing a Lf-
nanoparticle complex which was then examined using a fluorescent probe coumarin-6. 
There was a higher amount of coumarin-6-loaded Lf-nanoparticles in bEnd.3 cells than of 
unmodified nanoparticles in uptake studies. Moreover, intravenous administration of 
coumarin-6 containing Lf-nanoparticles yielded quantities 3 fold greater than that of 
coumarin-6 integrated in unconjugated nanoparticles in the mouse brain. Lactoferrin thus 
has great potential of ensuring that therapeutic agents are taken up by endothelial cells of 
BBB therefore crossing the BBB and increasing their yield at their target site. In the study, 
the drug delivery system was used for the delivery of UCN for therapy in PD but just like the 
previous system, its potential can be translated to therapeutic agents used for therapy in 
ALS. 
2.6.3. Huntington’s disease 
Gene therapy has been at the forefront of the search for breakthrough treatment for HD. The 
development of non-viral, nanoparticulate vectors for gene delivery has received much 
attention. These vectors could be beneficial for, not only research in HD therapy, but for 
other disorders that are caused by gene defects including ALS. Below are examples of such 
innovations in HD. 
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2.6.3.1. Nanotechnologies employed in Huntington’s disease 
2.6.3.1.1. Organically modified silica (ORMOSIL)-DNA nanoplexes 
Techniques have been developed by Stachowiak and co-workers (2009), to bind DNA on the 
surface of organically modified silica nanoparticles (ORMOSIL) to create nonviral vectors for 
the safe and efficient delivery of genes. These methods were developed specifically to target 
the integrative nuclear FGF Receptor 1 signalling (INFS) pathway which is responsible for 
the development of neural stem/progenitor cells (NS/PCs) in vitro (Stachowiak et al., 2009). 
ORMOSIL nanoparticles have both hydrophobic and hydrophilic groups on the precursor 
alkoxy organosilane which plays a role in self-assembly of both normal and reverse micelles 
under suitable conditions (Modi et al., 2010). These nanoparticles are formed using the oil-
in-water micro-emulsion method that evades corrosive solvents and undergoes an intricate 
purification process. ORMOSIL-DNA nanoplexes were used to induce neurogenesis in 
transfected NS/PCs of an adult mouse brain. Nanoplexes carrying the recombinant nuclear 
form of FGF Receptor 1 (FGFR1) stimulate NS/PC withdrawal from the cell cycle and 
neuronal differentiation in vivo. Stachowiak and co-workers (2009) were able to demonstrate 
that nanoparticle-mediated gene delivery in NS/PCs promotes neurogenesis through the 
INFS mechanisms in vivo.  
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Table 2.3: A summary of Alzheimer’s disease, Parkinson’s disease and Huntington’s 
disease. Symptoms, incidences and nanotechnologies investigated for their treatment 
Neurodegenerative 
Disease 
Symptoms 
Worldwide 
Incidence  
Current 
Medication 
Examples of  
Nanosystems Used  
Alzheimer’s disease 
(AD) 
Progressive short-
term memory loss, 
behavioural 
symptoms, 
functional 
deficiencies, mood 
disorders, anxiety, 
psychotic episodes 
and aggression 
(Gauthier  et al., 
2005)  
 
33.9 million 
(Barnes DE, 
Yaffe, 2011) 
Cholinesterase 
inhibitors, 
memantine, 
selegiline, Gingko 
biloba (Schmitt et 
al., 2004)
 
 
 
 Gold nanoparticles for detecting 
AD biomarker (Neely et al., 
2009)  
 Cerium oxide nanoparticles 
(Singh et al., 2007)  
 Clioquinol-loaded N-
butylcyanoacrylate 
nanoparticles (Modi et al., 2010)  
 Inhibition of β-amyloid plaque 
formation using nanoparticles 
(Cabaleiro-Lago et al., 2008) 
 D-penicillamine nanoparticles 
for the treating AD (Cui et al., 
2005)  
Parkinson’s disease 
(PD) 
Cognitive 
dysfunction, 
movement 
impairments, 
dementia (Kehagia 
et al., 2010)  
 
8-18/100000 
(de Lau and 
Breteler, 
2006)  
Levodopa, 
selegiline, COMT 
inhibitors, 
dopamine 
agonists, 
anticholinergic 
drugs, 
amantadine, 
apomorphine 
(Jankovic and 
Aguilar, 2008)  
 
 Delivery of dopamine using 
chitosan nanoparticles (Trapani  
et al., 2011)  
 Nanoparticle-based gene 
therapy (Yurek et al., 2009)  
 Nanofibers as stem cell therapy 
(Nisbet et al., 2008) 
 Carbon nanotube and gold 
nanoparticle biosensors for 
detection of PD (Tisch et al., 
2013) 
 
 
Huntington’s 
disease (HD) 
Chorea and 
dystonia, 
personality 
changes, cognitive 
dysfunction 
(Walker, 2007)  
 
2.71/100000 
(Pringsheim  
et al., 2012)  
Antipsychotics, 
antidepressants, 
tranquilizers, 
mood stabilizers, 
botulinum toxin, 
tetrabenazine 
(xenazine) 
(Gudesblatt and 
Tarsy, 2011)   
 
 Organically modified silica 
(ORMOSIL)-DNA nanoplexes 
(Stachowiak et al., 2009)  
 Self-assembling β-cyclodextrin 
nanoparticles (Godinho et al., 
2013)  
 
 
 
 
 
 
2.6.3.1.2. Self-assembling β-cyclodextrin nanoparticles 
Modified amphiphilic cationic β-cyclodextrin (β-CDs) nanoparticles were developed as 
carriers of short interfering RNAs (siRNAs) for the treatment of HD (Godinho et al., 2013). 
The use of siRNAs is to target the silencing of the mutant huntingtin protein (Godinho et al., 
2013). The positively charged β-CDs are suggested to have an interaction with the anionic 
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huntingtin targeted siRNAs which in turn produced nanoparticles. These nanoparticles were 
found to show great stability in simulated cerebrospinal fluid. In addition, the use of this 
nano-sized delivery system in this study resulted in a decrease in the expression of the 
huntingtin gene in the rat striatal cells and in human HD primary fibroblasts. Frequent 
injections of the nanoparticles mitigated some of the motor symptoms in the R6/ 2 mouse 
model of HD. These findings point towards β-CD nanoparticles being potentially used in the 
application of HD treatment. Both delivery systems mentioned for gene therapy in HD 
treatment have potential in ALS research.  
 
2.7. Drug delivery nanosystems used for the treatment of ALS 
Since the BBB restricts the entry of a copious amount of xenobiotic molecules including 
drugs, it is very difficult to efficiently achieve purposeful recovery in neurodegenerative 
disorders. Nanotechnology is at the forefront of biotechnology and of overcoming this 
barricade (Modi et al., 2010). The low bioavailability of some therapeutic agents is possibly 
one of many problems that the agents tested in clinical trials have faced. Even though 
riluzole showed some success, it still doesn’t reach satisfactory therapeutic levels. Designing 
a proficient targeted nano-enabled drug delivery system and incorporating riluzole, or any 
other potential therapeutic agent, as the active agent has the prospective to advance its 
therapeutic profile. Polymeric nanoparticles are prospective components in developing a 
drug-delivery system for the treatment of neurodegenerative disorders such as ALS.  
 
Currently, according to our research, there have only been three attempts to develop ALS 
therapy combining nanotechnology with riluzole treatment. These attempts have all been at 
foundation stages and require further extensive investigation before reaching clinical 
implication. Moreover, as mentioned previously, ALS rat models have failed to translate to 
positive results for human trials. This means that, although promising, these nano-enabled 
systems would need to be tested on much improved ALS animal models. Since riluzole is an 
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anti-glutaminergic agent, the nano-enabled systems incorporating this drug would thus be 
targeting the irregular stimulation of glutamate receptors and block these receptors. 
 
Bondì and co-workers (2010) prepared riluzole-loaded solid lipid nanoparticles for the 
treatment of ALS. The lipophilic properties of these nanoparticles provided them with the 
ability to target the brain by endocytosis. The riluzole-loaded nanoparticles and conventional 
riluzole were administered to rats separately and the two were compared. The riluzole-
loaded nanoparticles were able to bypass the BBB and deliver an increased amount of drug 
to the brain as compared to conventional riluzole. Additionally, it was established that there 
was minimal drug in organs such as the spleen, liver, kidney and heart when the rats were 
given riluzole-loaded nanoparticles. Conversely, the drug bio-distribution was increased in 
these organs in the rats that received conventional riluzole. The entrapped riluzole reduced 
the concentration of drug in the bloodstream and therefore reduced side-effects that are 
apparent with conventional riluzole (Bondì et al., 2010). 
 
In a different study, carbon nanotubes (CNTs) were used as carriers for riluzole (Chigumbu 
et al., 2012). The physicochemical properties of CNTs such as their chemical composition, 
surface area, length, and diffusion in solution were adapted to enhance their employment in 
drug delivery. Riluzole was covalently bound to the CNTs after their modification, which in 
turn resulted in further alterations in CNT chemical structure. The in vitro study aimed to 
investigate the possible toxicity that the riluzole-bound multi-walled nanotubes could 
introduce to cells. After the comparison between cells treated with these nanotubes and 
untreated control cells, the cells were still alive and functional. This comparison verified that 
the riluzole-bound multi-walled nanotubes do not instigate cytotoxicity.  
 
Lastly, in an in vitro study by Shanmukhapuvvada and Vankayalapati (2012), chitosan 
nanoparticles were formulated to carry riluzole to the brain. In this investigation, chitosan 
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was cross-linked with tripolyphosphate using an emulsification method. The physicochemical 
properties of chitosan (hydrophilic and cationic) and the size of the nanoparticles permitted 
the targeting of the central nervous system by endocytosis or transcytosis. The optimised 
formulation with a size of 418nm showed drug entrapment of 55% and released 86.2% of the 
drug within 24 hours. Although this study provided no comparisons in vivo, it demonstrated 
that it is possible to design a system that has the potential to carry and deliver riluzole to the 
central nervous system. 
 
Additional studies incorporating agents other than riluzole have also shown that using 
targeted therapy or carrier-based therapy increases the chances of producing positive 
results. Minocycline, an agent that was previously reported to lack the desired efficiency, 
was encapsulated in lipopolysaccharide modified liposomes to target activation of microglia 
in SOD1 mice (Wiley et al., 2012). Wiley and co-workers (2012) aimed to prove that 
introducing nano-encapsulated minocycline intracerebroventricularly would increase site-
specific action of the drug and therefore delay the onset of ALS and increase lifespan in 
SOD1 mice. They also aimed to demonstrate that these minocycline-carrying nanovesicles 
could delay future disease development by reducing neuro-inflammation achieved by the 
activation of microglia. The TLR4 receptors on the microglia of SOD1 mice were targeted 
using the modified nanoliposomes and their efficacy was compared to non-targeted 
nanoliposomes. The in vitro results showed a 29% increase of drug uptake in BV-2 microglia 
cells when using nanoliposomes targeting the TLR4 receptors on microglia compared to 
non-targeted nanoliposomes. Both targeted and non-targeted nanoliposomes were able to 
delay disease onset in SOD1 mice. This study also showed intracerebroventricular 
administration of the minocycline-loaded nanoliposomes was more effective in the latency to 
the disease endpoints than when compared to the oral and injected minocycline. 
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2.8. Future Recommendations  
 
In view of the minimal existing therapy used in the treatment of ALS, the need for more 
pioneering approaches to unearthing an effective treatment with negligible side effects is 
highly evident. In addition, the BBB hinders the penetration of therapeutic agents into the 
brain thus necessitating a delivery system that will bypass this barrier and achieve high 
bioavailability. Incidentally, the use of nanotechnology as well as stem cells as carriers for 
therapeutic agents is a potential strategy. As mentioned in this review, a number of attempts 
have been made to develop treatment for ALS and only a few attempts using 
nanotechnology have been investigated. With only riluzole being FDA approved, it is clear 
that clinical trials have failed dismally to produce desirable results. 
 
The ideal brain delivery system should be biocompatible, biodegradable, present extremely 
low toxicity, require minimal drug to achieve maximum therapeutic levels and be able to 
carry a therapeutic agent and deliver it to its target site still in its active conformation; that is, 
be a targeted delivery system. It should also be able to retain the therapeutic agent at the 
target site for a prolonged period, degrade slowly and thus provide a sustained delivery of 
the therapeutic agent and also be practicable. Not much is being done to explore such 
delivery systems in the treatment of ALS. Considering that there are numerous theories to 
the pathophysiology of ALS, perhaps a multifunctional delivery system could bring about 
much desired results. Therapeutic agents that have been tested have shown little to no 
effect therefore a combination of these agents, incorporated in a multifunctional system 
would be an interesting avenue to investigate. Furthermore research has been done into 
implantable and/ or injectable polymeric hydrogels for the treatment of tumours and other 
illnesses (Hatefi and Amsden, 2002; Schmaljohann, 2006). These could possibly be 
beneficial when designing a delivery system that can provide all the characteristics 
mentioned earlier. Polymeric hydrogels have been shown to have features that are very 
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useful in a delivery system, including slowly degrading to release a therapeutic agent 
activated by an external stimulus such as temperature. A combination of nanoparticles with 
the hydrogel could bring about great benefits from both systems. This has been attempted 
for the treatment of other diseases such as cancer (Gong et al., 2012) and could be used to 
develop a system for ALS.  
 
The issues that have been identified with the process of discovering or inventing an effective 
treatment include the difficulty in designing and performing clinical trials. This is an aspect 
that needs to be thoroughly investigated and improved significantly. An improvement in the 
way clinical trials are designed and run could possibly result in an increase in the amount of 
FDA approved therapeutic agents. Many clinical trials have been based on a two-arm, 
parallel study design and a few have attempted the crossover design, a sequential study 
design, and others for a different option (Levy et al., 2006). However, designs have not 
produced positive outcomes because of the difficulties associated with managing ALS, the 
lack of biomarkers for early diagnosis, the research that still needs to be done to measure 
the effect of a drug and to detect realistic effect size together with methods to minimize 
missing data and selecting suitable dose, regimen and route. In addition, ALS has a short 
disease duration therefore patients in the trial will likely not be able to be in the study for a 
long period of time.  Many other considerations such as the ones mentioned need to be 
made in the designing of ALS clinical trials and this could possibly change the state this 
disorder is currently in. 
  
2.9. Concluding Remarks 
 
Carrier-based therapy in neurodegenerative diseases has shown to have potential in 
eradicating the problems associated with the extensive neuron damage of ALS and the BBB. 
The advantage that nanotechnology offers with regard to nano-scale formation enables it to 
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be at the forefront of efficiently delivering genes and drugs to affected areas with reduced 
side effects and less difficulty in crossing the BBB. Biological components such as stem cells 
provide both a delivery system for therapeutic agents as well as bringing their own benefits 
in protecting motorneurons. Many therapeutic agents have been found unsuccessful in 
countless clinical trials possibly as a result of a number of problems including low 
bioavailabilities and detrimental side effects. The introduction of nanotechnology or stem 
cells to these agents could yield better results than those achieved previously. ALS has had 
many failed therapeutic agents and, to our knowledge, investigations into the implementation 
of nanotechnology as a solution to improving treatment have been minimal. The use of 
biodegradable and biocompatible polymers to formulate nanosystems that are able to 
support the regeneration of damaged neurons, promote neuroprotection and transport 
therapeutic agents should be exploited in developing treatments for ALS. It would be 
intriguing and valuable to utilise nanotechnology to improve the efficiency of some of the 
ALS therapeutic agents that provided minimal success in clinical trials previously. The result 
could possibly be one that translates to positive outcomes in ALS patients. 
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CHAPTER THREE 
PREFORMULATION ANALYSIS OF THE DRUG AND COMPONENTS INTENDED 
FOR NANOSPHERE PREPARATION 
3.1. Introduction 
The diverse methods and materials used for the preparation of nanoparticles have improved 
vastly over the years and the quest for finding the most pertinent and efficient of these is still 
in progress. The process required to prepare suitable and effective nanoparticles involves 
researching the properties of different polymers that will maximise the efficiency of those 
particles, investigating the organic solvent that the polymers dissolve in, the ratio of the 
concentration of polymers and organic solvent as well as finding a suitable stabiliser.  
Polymethacrylates, also known as Eudragits®, have conventionally been used for the coating 
of tablets and capsules to achieve masking of taste for increased patient compliance (Nikam 
et al., 2011) and, more importantly, to prevent the release of active agents before they reach 
their target site. They are synthetic cationic and anionic polymers of dimethylaminoethyl 
methacrylates, methacrylic acid, and methacrylic acid esters in different ratios (Evonik 
Industries: Eudragits, 2013). A number of them are available commercially as either the dry 
powder, as an aqueous dispersion, or as an organic solution. The ability that these unique 
polymers have to control the location and time of release of active agents has undoubtedly 
led to an expansion of their pharmaceutical application to the formulation of nanoparticles.  
Likewise, polylactides are well established natural polymers that have been used extensively 
in the preparation of various nano-sized controlled release drug delivery systems. Their 
appeal is largely based on their biodegradability and biocompatibility properties (Ahmed et 
al, 2009). This is highly advantageous as it eliminates the need for surgical removal of 
foreign material in the body once the drug-load has been exhausted. Lactides can be found 
in three diasteroimeric forms (see figure 3.1): L-lactide, D-lactide and DL-lactide (PDLLA) 
which is an amorphous racemic mixture of the D and L isomer. Any of these forms can be 
used in the formation of nanoparticles. 
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                 a)    b)   c)  
Figure 3.1: a) Poly-D-Lactide b) Poly-L-Lactide c) Poly-D,L-Lactide 
 
The most desirable nanoparticles are stable, very small in size (< 300 nm) and for some 
applications must be small enough for cellular uptake. A blend of polymethacrylates and 
polylactides in the preparation of nanoparticles is worthwhile to explore as their properties 
indicate that a combination of these polymers has the potential to produce highly stable and 
functional nanoparticles. However, because polymethacrylates can either be cationic or 
anionic, the charge they carry is vital in how they interact with other polymers and therefore 
will exhibit different behaviours accordingly. Polylactides are ordinarily uncharged molecules; 
conversely, because they encompass a carboxyl group they are able to exist as zwitterions 
or polyelectrolytes at neutral pH level. This means it is possible for them to form 
polyelectrolyte complexes when mixed with polyions. 
Polyelectrolyte complexes (PECs) or interpolyelectrolyte complexes form when oppositely 
charged polyelectrolytes (polyanions and polycations) are dissolved in an aqueous solution 
as seen in figure 3.2 (Buchhammer, et al., 2003). An electrostatical interaction occurs 
between the two polymers resulting in involuntary aggregation. This aggregation is caused 
by the increasing entropy that occurs when counterions of low molecular weight are 
discharged from the polymers (Paneva, et al., 2007). Polyelectrolyte complex nanoparticles 
have been formed using Poly(ethyleneimine) and Poly(acrylic acid) where it was determined 
that pH, molecular weight, mixing ratios, mixing order and polyelectrolyte concentration are 
parameters that regulate nanoparticle size (Müller, et al., 2011).  
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Figure 3.2: Oppositely charged polyelectrolytes mixed in an aqueous solution form an 
interpolyelectrolyte complex. A Monte Carlo spatial (non-lattice) model can demonstrate this 
reaction where stiff chains are organised into a ‘‘ladder’’ structure in which chains are 
located parallel to each other and monomeric units are arranged into ionic pairs according to 
their position in the chain. Flexible chains form a globular ‘‘scrambled-egg’’ structure with a 
disordered position of monomer units (Pergushov et al., 2012) 
 
It has been suggested that there are two steps in the formation of polyelectrolyte complex 
nanoparticles. Primary polyelectrolyte complexes as described earlier are bound by 
electrostatic interactions and this process is usually followed by the formation of secondary 
polyelectrolyte complexes which are primary PECs that are bound by short range dispersive 
interactions. This may lead to secondary aggregation which presents as water-insoluble 
complexes and thus the formation of unstable nanoparticles. 
For the simulation of PEC structures, Lazutin and co-workers (2012) used a Monte Carlo 
spatial (non-lattice) model. They acknowledged excluded volume interactions, bond-length 
and bond angle constraining potentials, sticky interaction within ionic pairs as the 
interactions between monomeric units. The excluded volume interaction of non-bonded 
monomer units Eex is described by hard sphere potential: 
 
Eex =  
 
 
    rij >1                                                                                                     Equation 3.1 
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where rij is the distance between monomeric units i and j. Distances here and below are 
measured in units of monomer size α.  
The chain structure is imposed by bond length constraining potential Eb between 
neighbouring monomer units; it is taken in the form of a square-well potential: 
 
Eb =  
  
 
    1 < r <1.2                                                                                              Equation 3.2 
                
 
where r is the distance between neighbouring units. Thus, the bond length b is limited within 
the interval from b = 1 to b = 1.2. The value of maximum bond length b = 1.2 together with 
maximal displacement of Monte Carlo step  rmax = 0.1 was chosen so that the condition of 
non-phantom chain was automatically satisfied. To model the macromolecule backbone 
stiffness, the bending potential Estiff that depends on the angle θ between the adjacent bond 
vectors bi and bi + 1 was introduced, 
 
Estiff = 0.5εstθ
2                                                                                                                                                                   Equation 3.3 
 
where εst is the stiffness coefficient. The total energy Ebond defining the ionic pair formation is 
equal to 
 
Ebond = -εbondnbond                                                                                                                                                         Equation 3.4 
 
where nbond is the total number of salt bonds formed between charged units of a PEC. A salt 
bond AB is considered to exist if the distance between two units, A and B, belonging to 
different chains is smaller than rbond.  
 
In an effort to find the best combination of polymethacrylates with PDLLA for the preparation 
of nanospheres, both cationic and anionic polymethacrylates were investigated and their 
physicochemical properties were analysed and compared. The anionic polymethacrylates 
(a.PMA) investigated were Eudragit S100, L100 and L100-55. These are normally used as 
enteric coatings because they are resistant to gastric fluid. Eudragit E100 and RS PO were 
the cationic polymethacrylates (c.PMA) investigated. (See Table 3.1) 
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Table 3.1: Summary of properties of polymethacrylates 
Eudragit® 
(Trade 
name) 
Chemical name Charge 
Solvents 
or 
diluents 
Supply 
form 
Solubility/ 
permeability 
L100 Poly (methacrylic acid, methyl 
methacrylate) 1:1 
Anionic Acetone, 
alcohols 
Powder Soluble in 
intestinal fluid 
from pH 6 
S100 Poly (methacrylic acid, methyl 
methacrylate) 1:2 
Anionic Acetone, 
alcohols 
Powder Soluble in 
intestinal fluid 
from pH 7 
L100-55 Poly (methacrylic acid, ethyl 
acrylate) 1:1 
Anionic Acetone, 
alcohols 
Powder Soluble in 
intestinal fluid 
from pH 5.5 
RS PO Poly (ethyl acrylate, methyl 
methacrylate, 
trimethylammonioethyl 
methacrylate chloride) 1:2: 0.1 
Cationic Acetone, 
alcohols 
Powder Low 
permeability 
E100 Poly (butyl methacrylate, (2-
dimethylaminoethyl) 
methacrylate, methyl 
methacrylate) 1:2:1 
Cationic Acetone, 
alcohols 
Granules Soluble in 
gastric fluid to 
pH 5 
 
Poly-D,L-lactide was selected to form nanospheres together with the above mentioned 
polymethacrylates respectively. The effects cationic and anionic polymethacrylates have on 
PDLLA nanospheres were established as well as the elements that contribute to the stability 
or lack thereof of these nanospheres. 
3.2. Materials and Methods 
3.2.1. Materials 
Poly (D,L-lactide) (PDLLA) Resomer R203H was purchased from Boehringer Ingelheim 
Pharma GmbH (Ingelheim am Rhein, Germany). Polymethacrylates (Eudragit® L 100; S 100; 
L100-55; RS PO; E100) were purchased from Degussa, Rohm GmbH, Pharma Polymers 
(Germany). Amantadine HCl was purchased from Sigma-Aldrich Inc., (St Louis, MO, USA).  
Isopropyl alcohol and dichloromethane were purchased from Rochelle Chemicals 
(Johannesburg, South Africa). All other reagents used were of analytical grade and were 
used as purchased. 
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3.2.2. Determination of amantadine 
It was necessary to firstly establish a method for the determination of the chosen study drug, 
amantadine. The analytical techniques reported for amantadine HCl consist of high-
performance liquid chromatography, gas chromatography, capillary electrophoresis, 
potentiometry, and fluorimetry. The amantadine molecule lacks chromophores and/ or 
auxochromes, therefore, shows no distinct absorption in the UV region above 200 nm. 
Consequently direct UV spectrophotometry is not valuable for its quantitative determination. 
A number of spectrophotometric methods have been reported for its determination however, 
these methods have been found to be too complicated to perform, require derivatisation of 
the drug and are time consuming (Darwish et al., 2005; Mahmoud et al., 2009). 
 
                                    
Figure 3.3: Amantadine hydrochloride  
 
Spectrophotometric and fluorimetric analysis are considered more convenient alternative 
techniques because of their inherent simplicity and high sensitivity. Studies have described 
the improvement of effortless and sensitive spectrophotometric methods for determination of 
amantadine HCl. These methods include one based on the oxidation of the drug by either 
ammonium molybdate (Sridevi and Yusuff, 2007) or potassium permanganate, one based on 
the charge-transfer complexation reaction between the amantadine base as an electron 
donor and iodine as a σ-acceptor, as well as one based on the formation of coloured 
vinylamino-substituted benzoquinone derivative as a result of condensation of amantadine 
with acetaldehyde-chloranil combination (Darwish et al., 2006).  
a) Different methods of Amantadine determination 
The charge-transfer complexation reaction and the formation of coloured vinylamino- 
substituted benzoquinone derivative require slightly more effort than the oxidation method. 
The preparation of standard solutions for these methods involves accurately weighing out 
100 mg of amantadine HCl and dissolving it in 10 ml of distilled water in a 25-ml beaker. The 
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solution is then transferred quantitatively into a 100 ml separating funnel, rendered alkaline 
with ammonia solution, and the excess ammonia is evaporated by heating the solution in a 
water bath. The liberating base is extracted with four 25 mL portions of chloroform. The 
combined extracts are passed through a small funnel containing anhydrous sodium sulphate 
(2 g) into a 100 mL calibrated flask. The contents of the separating funnel are washed three 
times with chloroform. The combined extracts and washings are then diluted to the mark with 
the same solvent to obtain a stock standard solution of 1 mg.mL-1 of amantadine, calculated 
as hydrochloride salt. This stock solution is then diluted with 1,2-dichloromethane and 
isopropanol for the charge-tranfer complexation reaction and the formation of coloured 
vinylamino-substituted benzoquinone derivative, respectively, to obtain working solutions in 
the range of 2-400 μg.mL-1. 
Thereafter, the recommended procedure for the charge-transfer complexation reaction is as 
follows: 1 mL of the standard or sample solution (20-350 μg.mL-1) is transferred into 10 mL 
calibrated flasks. One milliliter of iodine solution (0.05%, 
w
/v in dichloromethane) is added, 
and the reaction is allowed to proceed for 20 min at room temperature (25 ± 5oC). The 
solution is diluted to volume with dichloromethane and the absorbances of the resulting 
solution are measured at 290 or 365 nm against reagent blanks treated similarly. 
For the formation of coloured vinylamino- substituted benzoquinone derivative: 1 mL of the 
standard or sample solution (20-400 μg.mL-1) is transferred into 10 mL calibrated flasks. One 
milliliter of the acetaldehyde solution (1%, 
v
/v in isopropanol) and 1 mL of chloranil (0.15%, 
w
/v in isopropanol) are added. The reactions are allowed to proceed for 10 min at room 
temperature (25 ± 5°C). The solution is diluted to volume with isopropanol, and the 
absorbances of the resulting solution are measured at 325 or 685 nm against reagent blanks 
treated similarly. 
b) Method chosen for study 
For this study, oxidation of amantadine by potassium permanganate was used for 
determination of the drug as it was simpler and produced the most practical results (Khedr et 
al.). Briefly, an accurately weighed amount (1g) of amantadine HCl was transferred into 100 
mL calibrated flask, and dissolved in approximately 40 mL of deionised water. The resulting 
solution was completed to the mark with water to provide a stock solution containing 10mg/ 
mL. Different volumes of this stock solution were then further diluted with water to obtain the 
working standard solutions of concentrations suitable for analysis by potassium 
permanganate.  
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1 mL of the standard solution was transferred into a 10 mL calibrated flask. 1 mL of 
standardised KMnO4 reagent was added. 2 mL of sulphuric acid (H2SO4 20%) was added. 
The contents of the flasks were mixed and the reaction was allowed to proceed for 15 
minutes at room temperature (25 ± 5 ºC). After completion of reactions, the solutions were 
completed to volume with water. The absorbances of the resulting solutions were measured 
at 525 nm against reagent blanks treated similarly. 
3.2.3. Synthesis of PDLLA-polymethacrylate nanospheres 
The nanospheres were prepared by a double emulsion solvent evaporation method. Briefly, 
the organic phase was prepared by co-dissolving the polymers PDLLA and Eudragit® (L100, 
L100-55, S100, E100 or RSPO) in a mixed solvent system comprising of dichloromethane 
and isopropyl alcohol in a ratio of 1:1. The internal aqueous-phase (1mL of deionised water) 
and the organic phase were homogenized (Polytron, PT 2000, KINEMATIKA, AG LITTAU, 
Switzerland) for 3min at room temperature (25±0.5oC) to form a primary emulsion. The 
external aqueous-phase was prepared by dissolving SPAN80 in phosphate buffer saline (pH 
7.4) to form a 0.25%v/v solution. The primary emulsion was added drop by drop to the 
external aqueous-phase and emulsification was continued for further 30 min using a 
sonicator to form nanoparticles. The formed emulsion was  centrifuged (Nison Instrument 
(Shangai) Limited, Shangai, China) at 15,000rpm for 10 minutes at 25oC, washed two times 
with distilled water and then lyophilized (LABCONCO, Kansas City, Missouri, USA) for 24 
hours.  
3.2.4. Determination of the size and charge of the nanospheres 
Particle size is resolved by dynamic light scattering (DLS) that quantifies the Brownian 
motion of the particles. Brownian motion is the phenomenon where smaller particle sizes 
move more rapidly than larger particles therefore exhibiting greater Brownian motion. 
 
The particle size is calculated from the translational diffusion coefficient using relaxation time 
of the Brownian motion (Stokes-Einstein equation) (Ma et al., 2004): 
 
              4πƞr3 
τB =       kT                                                                                                   Equation 3.5 
 
where r is the hydrodynamic radius of the particle, k is Boltzmann's constant, T is the fixed 
temperature and ƞ is the viscosity of the liquid/ solvent used. Temperature needs to be kept 
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constant to ensure that the viscosity of the liquid is maintained throughout the measurement 
process. 
 
The adsorption of a charged surfactant, the ionization of charged groups in the polymers 
used or the loss of ions from the recently formed nanospheres may result in particle surface 
charge or, alternatively the zeta potential. The surface charge may control the interactions 
with electrolytes found in the body and permanence of the formulation. 
 
The Derjaguin, Landau, Verwey and Overbeek (DLVO) theory can be used to determine the 
stability of particles (Jiang et al., 2009).  
 
Vt = Ve + Vd                                                                                                                                                       Equation 3.6 
 
where Ve and Vd are the forces of electrostatic born repulsion and van der Waals attraction 
respectively that exist between the particles. 
 
However, it has been recommended that to incorporate particles suspended in water, which 
will essentially have Lewis acid-base interactions, an extended-DLVO approach should be 
employed instead (Chang and Chang, 2002). 
 
V’t = Ve + Vd + Vs                                                                                                                                           Equation 3.7 
where Vs is the hydration energy. 
 
A charge of ±25mV is an indication of a stable formulation that will not aggregate. 
 
Polymers are made up of repeat components (monomers) which are chemically bonded into 
long chains. Chain length is defined by the molecular weight of the polymer chain, pertaining 
to the relative molecular mass of the monomers and the number of monomers attached to 
the chain (Rogosic et al., 1996). All synthetic polymers have polymer chains of unequal 
length which makes them polydisperse. This means that the molecular weight is more than 
one value (i.e. exists as an average molecular weight of all molecular weights of all the 
chains in the sample) and consequently, the polymer consists of a distribution of chain 
lengths and molecular weights. (Polymer molecular weight distribution and definitions of MW 
averages, 2014). 
 
The number average molecular weight (Mn) is the statistical average molecular weight of all 
the polymer chains in the sample, and is defined by equation 3.8: 
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Mn = ƩNiMi   
           ƩNi                                                                                                                                                         Equation 3.8 
where Mi is the molecular weight of a chain and Ni is the number of chains of that molecular 
weight. Mn is calculated by polymerisation techniques and is determined by methods that 
resolve the number of molecules in a sample of a given weight.  
The weight average molecular weight (Mw) is defined by equation 3.9: 
 
Mw = ƩNiMi
2  
           ƩNiMi                                                                                                                                                    Equation 3.9 
 
Mw considers the molecular weight of a chain to confirm the contributions to the molecular 
weight average. The larger the chain, the more the chain contributes to the Mw. Mw is 
calculated by processes that are perceptive to the molecular size as well as the number, 
such as light scattering methods.  
 
Commonly, a succession of average molecular weights can be defined by the equation: 
 
M = ƩNiMi
n + 1 
         ƩNiMi
n                                                                                                                                                     Equation 3.10 
 
where: n = 1 gives M = Mw 
            n = 2 gives M = Mz 
            n = 3 gives M = Mz + 1 
 
The higher the averages, the more sensitive they are to high molecular weight polymers and 
as a result are increasingly more complex to measure meticulously. They are usually 
associated with methods that measure the motion of polymer molecules, such as diffusion or 
sedimentation techniques.  
 
For all synthetic polydisperse polymers: 
 
Mn < Mw < Mz < Mz+1 
 
The polydispersity index is used as a measurement of the broadness of a molecular weight 
distribution of a polymer and is defined by: 
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Polydispersity index = Mw 
                                     Mn                                                                                   Equation 3.11 
The larger the polydispersity index, the broader the molecular weight. 
 
Determination of the average particle size, polydispersity index (Pdi) and zeta potential of 
the nanospheres was completed using a Zetasizer NanoZS instrument (Malvern Instruments 
(Pty) Ltd., Worcestershire, UK) at 25°C. All nanosphere particle size and zeta potential 
measurements were performed in the same manner. Each sample was diluted (1 in 10) with 
deionised water using disposable cuvettes for each run. Each test was performed in triplicate 
and the average value in each case was reported accordingly. 
 
3.2.5. Study of the stability of the nanosphere emulsions 
The stability of the emulsions was determined employing a Turbiscan Lab® (Turbiscan 
LabTM, Formulaction SA, L’Union, France). The Turbiscan Lab® assessed the phenomena 
affecting the homogeneity of the emulsions which consists of particle migration resulting in 
creaming or sedimentation as well as particle size variation or aggregation causing 
coalescence or flocculation. The Turbiscan Lab® Expert software was used to study 
transmitted (T) and backscattered (BS) light relating to equation 3.12. The transmission of 
light in a random dispersed medium may be considered as independent when the photon 
mean path length λ*(Ф,d) is larger than the wavelength Λ of the incident radiation as seen in 
equation 3.13 
 
               1 
BS =      √λ*                                                                                                                                     Equation 3.12 
 
                            1                                       2d 
λ*(Ф,d) =          n (πd2/4) Q e        =         3 Ф Q e                                                                       Equation 3.13 
 
            π d3 
Ф = n  
               6                                                                                                                                     Equation 3.14 
 
Where λ* is the photon transport mean free path, Ф the particle volume fraction, n is the 
particle density, d the particle mean diameter and Q e the extinction efficiency factor for 
scattering and absorption phenomena. Non-absorbing particles with an extinction efficiency 
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factor Q e equals to the scattering efficiency factor Q s which is an optical parameter given 
by the Mie theory. A particle can emit anisotropic scattering of light which can be 
characterised by the asymmetry factor g, which is the average cosine <cosθ> of the 
scattering angles weighted by the phase function or scattering diagram P(θ) of the scatterer 
(g = 0 for isotropic Rayleigh scatterers and 0 < g < 1 for Mie scatterers of sizes larger than 
the wavelength). 
Poly-DL-lactide polymethacrylate nanosphere emulsions were poured into flat bottomed 
boroscillated glass cells (27.5x70mm) up to a height of approximately 40mm then placed into 
the Turbiscan Lab® instrument. Synchronous dual measurements were performed by the 
transmission detector (at 180°) that receives the light, which went through the samples, while 
the backscattering detector (at 45°) received the light scattered backward by the samples. 
The light source has pulsed infrared with a wavelength of 880nm. Measurements were 
performed at 25°C and the Turbiscan Lab® was configured to perform scans for 5 minutes 
for each sample, over a 55mm cell length from bottom to top acquiring transmission and 
backscattering data every 40 μm. Deviation in particle volume fraction (Ф) on particle 
migration (sedimentation or creaming) and the mean particle diameter (d) attributable to 
coalescence resulted in variation in the magnitude of transmitted and back-scattered light. 
The measured amount of transmitted and backscattered light was then interpreted and used 
to describe the dispersion state (stability) of the emulsion. 
 
3.3. Results and discussion 
3.3.1. Amantadine detection 
Potassium permanganate is a strong oxidant with an intense violet colour of λmax 525 nm. 
The oxidation of organic compounds with potassium permanganate has been found to be pH 
dependent. During the course of the reaction, the valance of manganese changes and the 
intermediate ions are suggested to be participating oxidants. The species that are 
considered as potential oxidants depend on the nature of the substrate and the pH of the 
medium (Asghar and Fawzy, 2014). In strong acidic medium, potassium permanganate 
(KMnO4) produces the Mn
2+ for a net transfer of five electrons. In neutral or basic media 
manganese dioxide (MnO2) is formed with corresponding net transfer of three electrons.  
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Figure 3.4: Inverse calibration curve for amantadine HCl 
Potassium permanganate has an oxidizing effect on amantadine HCl in acidic solutions. This 
is shown by the decrease in the violet colour of potassium permanganate at 525 nm. This 
decrease in colour was used as a measure for the concentration of the drug. This is the 
reason the calibration curve for amantadine HCl is an inverse curve instead of the 
conventional curve. Amantadine HCl has no absorption capabilities in the region of 
measurements of potassium permanganate at 525nm. 
3.3.2. Physicochemical properties of the nanospheres 
Physicochemical characterisation of the nanospheres was determined using Dynamic Light 
Scattering (Zetasizer NanoZS, Malvern Instrument, UK). The average size of the 
nanospheres formulated with anionic polymethacrylates ranged from 134.1nm to 160.7nm 
(see table 3.2). However, the two PDLLA-c.PMA combinations yielded average sizes above 
300nm (366.8nm and 338.0 for PDLLA-E100 and PDLLA-RSPO respectively). Ideally, any 
nanoparticles should have sizes below 300nm. The PdI value of the PDLLA-a.PMA 
combinations ranged from 0.231 to 0.276 whereas the PDLLA-c.PMA combinations had 
values much closer to 0.5 (the upper limit for an ideal PdI value). As mentioned in the 
introduction of this chapter, in a neutral pH (the organic phase is neutral); PDLLA is able to 
exist as a polyelectrolyte because it encompasses a carboxyl group. It is thus possible for 
y = 0.1023 + -0.1062x 
R2 = 0.9920 
 
56 
 
PDLLA to form a polyelectrolyte complex when mixed with the charged PMAs. Results show 
that PDLLA combined with the cationic PMAs in nanosphere preparation resulted in large 
unstable particles which presented as aggregates during nanosphere formulation. It is 
possible that unstable polyelectrolyte complexes were formed. 
 
Table 3.2: Physicochemical characterisation of nanospheres 
Composite 
Polymethacrylate 
DLS size (nm) 
Polydispersity Index 
(0-1) 
Zeta Potential (mV) 
PDLLA-L100 160.7 0.276 -24.9 
PDLLA-L100-55 150.0 0.231 -25.9 
PDLLA-S100 134.1 0.249 -29.2 
PDLLA-E100 366.8 0.465 -12.9 
PDLLA-RS PO 338.0 0.447 -27.1 
 
a)  
b)  
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c)  
d)  
e)  
Figure 3.5: Size distributions by intensity showing the more stable PDLLA-a.PMA 
nanospheres a) PDLLA-L100 nanospheres; b) PDLLA-L100-55; c) PDLLA-S100 and the 
less stable PDLLA-c.PMA nanospheres d) PDLLA-E100 and e) PDLLA-RSPO 
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3.3.3. Morphological characterisation of the nanospheres 
Distinctive TEM images of the PDLLA-a.PMA nanospheres verified that nanosized and 
spherical particles were formed. Figure 3.6a-c shows the characteristic images of PDLLA-
a.PMA nanospheres. Figure 3.6d and 3.6e show the larger PDLLA-c.PMA nanospheres. The 
zwitterionic nature of PDLLA resulted in a negative charge on the polymer in aqueous 
solution (the hydrogen on the carboxyl group gets released and leaves the carboxyl group 
negatively charged). The addition of cationic polymethacrylates to the PDLLA resulted in the 
interaction of a positively charged polyelectrolyte (carried by the nitrogen) with a negatively 
charged polyelectrolyte thus forming unstable polyelectrolyte complexes. 
 
Figure 3.6: TEM micrographs of a) PDLLA-L100; b) S100; c) PDLLA-L100-55; d) PDLLA-
E100 and e) PDLLA-RS PO nanospheres. Arrows indicating individual and clusters of 
nanospheres. 
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3.3.4. Stability of the nanosphere emulsions 
The migration behaviour and aggregation propensity of all the nanosphere formulations were 
observed using the Turbiscan®. Results indicated that the PDLLA-L100, PDLLA-L100-55 
and the PDLLA-S100 nanospheres had minimal motion in the suspension and no 
aggregation (Figure 3.7a-c). However, PDLLA-L100 nanospheres (Figure 3.7b) were the 
most stable of the PDLLA-a.PMA nanospheres with a small amount of local destabilisation 
which can be seen by the slight wavering in the delta backscattering signal at the top end of 
the glass cell. The destabilisation is more prominent in the PDLLA-S100 nanospheres.  
Comparably, the PDLLA-E100 as well as the PDLLA-RSPO nanospheres gave off 
fluctuating backscattering signals throughout the entire length of the borosilicated glass cells 
(Figure 3.7d-e). This confirms that some of the polymer did not dissolve completely during 
the formation of the nanospheres and the fluctuating backscattering signals are indicative of 
free flowing polymer in solution. These results point towards the combination of PDLLA with 
the anionic polymethacrylates as being the more suitable composite for the formation of 
these nanospheres. The difference in the formulations is also shown in Figure 3.8 with high 
levels of aggregation in the PDLLA-c.PMA nanospheres. 
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Figure 3.7: Turbiscan graphs of delta backscattering 3.7a – 3.7c anionic eudragits and 3.7d 
& 3.7e cationic eudragits: 3.7a) PDLLA-L100-55 nanospheres; 3.7b) PDLLA-L100 
nanospheres; 3.7c) S100 nanospheres; 3.7d) E100 nanospheres; 3.7e) RS PO 
nanospheres 
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a)  
b) c)  
Figure 3.8: Different nanosphere formulations in the beakers they were prepared in. Figure 
3.8a shows the nanospheres prepared with anionic polymethacrylates. They appear 
completely homogenous without any residual polymer. Figure 3.8b and 3.8c show 
nanospheres prepared with cationic polymethacrylates. These had some polymers that did 
not completely dissolve or aggregated during the formation of the nanospheres. The arrows 
are pointing to the residual polymers that accumulated around the beakers and fluctuated to 
the top of the solution. 
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3.3.5. X-ray diffraction (XRD) of the nanosphere formulations 
X-ray diffraction (XRD) analysis of the various nanosphere formulations was performed to 
determine peak intensity, position and width. Figure 4.10 depicts the XRD diffractograms of; 
nanospheres prepared with PDLLA and L100, S100, L100-55, RS PO and E100. The 
diffractograms show similar peaks but at different intensities. The diffractograms also show 
that the formulations were mostly amorphous as a result of the amorphous polymers used. 
The two major peaks observed at 32.374º and 46.093º, however, are a contribution from 
polymethacrylates which have been found to have slight crystallinity. It has also been 
reported that the sharpness of the peaks indicate that the particles are in the nano-
arrangement (Saxena et al., 2012). It is possible, however that the resulting (common) 
diffractograms are due to the sample holder and not the actual sample. 
 
a)  
b)  
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c)  
d)  
e)  
Figure 3.9: XRD pattern of the different nanosphere formulations. They all have similar 
sharp peaks due to the slight crystallinity found in the polymethacrylates and are indicative of 
particles in the nano-scale. 
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3.4. Concluding remarks 
Physicochemical characterisation of the various PDLLA-PMA nanospheres was undertaken 
using Dynamic Light Scattering. Results showed that nanospheres prepared with cationic 
polymethacrylates were highly unstable with polydispersity indexes that were close to 0.5. 
Cationic polymethacrylates resulted in nanospheres with sizes over 300nm and unstable 
size distributions. Conversely, nanospheres prepared with anionic polymethacrylates were 
stable and had much smaller sizes. The negatively charged nanospheres had polydispersity 
indexes closer to zero and narrow and stable size distributions. 
 
Additionally, stability studies were performed using the Turbiscan® Lab instrument. These 
studies showed that PDLLA-c.PMA nanospheres produced fluctuating backscattering signals 
throughout the entire length of the borosilicated glass cells indicating unstable particles most 
likely to be polyelectrolyte complexes. PDLLA-a.PMA nanospheres, however, were shown to 
be more stable with PDLLA-L100 showing the most stability of the nanosphere emulsions. 
 
Essentially, the results indicate that the PDLLA combination with anionic polymethacrylates 
is far more desirable than the combination with cationic polymethacrylates. Anionic 
polymethacrylates form much weaker bonds with PDLLA which allows for some repelling of 
the particles and therefore decreased chances for aggregation. On the contrary, cationic 
polymethacrylates form stronger bonds with PDLLA which leads to a propensity for 
aggregation. The PDLLA-a.PMA combination, therefore, has the potential of contributing 
towards the formation of physically stable nanospheres in terms of size, PdI and zeta 
potential.  
 
  
65 
 
CHAPTER FOUR 
FORMULATION AND CHARACTERISATION OF AMANTADINE-LOADED PDLLA-
EUDRAGIT® NANOSPHERES 
 
 
4.1. Introduction 
MND is a term describing a rare group of progressive neurodegenerative diseases (Burvill, 
2009). It is divided into several classes, such as Amyotrophic Lateral Sclerosis (ALS), Spinal 
Muscular Atrophy (SMA), Primary Lateral Sclerosis (PLS) and Progressive Bulbar Paralysis 
(PBA) (Wu, 2005). ALS is the most common form of MND with an incidence of 2 in 100,000 
in most populations (Barber et al., 2006). It is caused by degeneration of both upper motor 
neurons in the motor cortex and lower motor neurons connecting the spinal cord and brain 
stem to muscle fibers (Barber and Shaw, 2010). The onset of majority of ALS patients 
typically develops between 40-60 years of age, resulting in eventual paralysis, speech 
deficits and ultimately death due to respiratory failure within 2–5 years of clinical onset 
(Julien, 2001).  
There are currently many theories concerning ALS pathogenesis, one of them being 
oxidative stress (Barber and Shaw, 2010).  Familial ALS (FALS) is associated with mutations 
to the copper, zinc dismutase protein (SOD1) which results in a toxic gain of function (Raoul 
et al., 2005; Kabashi et al., 2010; Saccon et al., 2013; Vanden Broeck et al., 2014). A variety 
of anomalous oxidative reactions catalyzed by mutant SOD1 have been proposed to 
contribute to this new toxic function. These commonly presuppose that the conformation of 
mutant SOD1 is more open than the wild-type protein, allowing substrates other than 
superoxide to penetrate the active site and react with the copper and zinc ions enclosed 
inside (Bruijn  et al., 1998; Barber et al., 2006). Usually, SOD1 catalyzes dismutation of 
superoxide radicals to hydrogen peroxide and oxygen in a redox reaction entailing reduction 
and reoxidisation of the copper ion in the active site of the dimeric protein. On the other 
hand, many ALS associated SOD1 mutants have been reported to show altered zinc 
binding, and the geometry of zinc-deficient SOD1 enables reducing agents other than 
superoxide (for example, ascorbate and glutathione) to react rapidly with the oxidised Cu2+ at 
the active site (Barber et al., 2006). It has been proposed that the reduced SOD1-Cu+ can 
produce superoxide in the reverse of its usual dismutase reaction, which reacts with nitric 
oxide within the active site to produce peroxynitrite, which then causes tyrosine nitration. 
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A number of therapeutic metal chelators such as ethylenediaminetetraacetic acid (EDTA), 
histidine residues and zinc acetate have been investigated for the prevention or reversal of 
Aβ aggregation in Alzheimer’s disease (Liu et al., 2009; Zatta et al., 2009). The aggregation 
is believed to be caused by a reaction of Aβ peptide with metal ions in the body (e.g. copper 
and zinc ions). These chelating ligands are easily taken up by cells and are able to remove 
unwanted ions. Chelating therapy has been approved by the US FDA for Alzheimer’s 
disease. It is useful to investigate it in ALS as well because of the similar oxidative stress 
pathogenesis.  
Although chelating therapy holds great potential in managing neurodegenerative disorders, 
factors such as bypassing the blood-brain barrier and toxic side effects remain problematic. 
Therapeutic agents, such as riluzole, the only FDA approved drug for ALS (Bellingham, 
2011), can have an improved bioavailability if carried by a nanoparticulate delivery system.  
Nanotechnology is the study of structures and materials at the nanoscale, comprising their 
fabrication, characterization and application. Natural or synthetic polymers are the most 
widely used materials for drug delivery and are used in a series of designs and formulations 
for the application of nano-carriers in pharmaceutical aspirations primarily because of their 
biodegradable and biocompatible properties. Other materials central to nano-carrier 
fabrication for drug delivery include macromolecules, lipids and proteins (Xu et al., 2010). 
Nanoscale drug delivery technologies consist of liposomes, dendrimers, nanotubes, 
nanomicelles, polymeric nanoparticles, nanospheres and nanoshells (Hughes, 2005). 
 
Nanoparticulate systems are beneficial in improving bioavailability of specific drugs that 
show a significantly low bioavailability in comparison to nanoscale drug delivery systems. 
Nanostructures are fabricated employing various techniques which include salting out, 
polymerisation (emulsion or interfacial) (Reis et al, 2006), coercervation or ionic gelation 
(Agnihotri et al, 2004) solvent displacement and interfacial deposition, emulsification solvent 
diffusion, supercritical or compressed fluid technology and emulsification solvent evaporation 
(Reis et al 2006). The emulsification solvent evaporation technique is a relatively simple and 
efficient way to prepare nanoparticulate systems that involves the dissolving of the drug, 
followed by the emulsification of the drug in an organic polymer solution. The resulting 
emulsion is then homogenised in an external aqueous or oil phase. While the organic 
solvent is eliminated by evaporation, the drug and polymer are precipitated in the droplets, 
thus forming nanoparticles. This technique can be performed under mild conditions in room 
temperature and constant stirring, thus resulting in a homogenous emulsion that evades the 
altering of the drug. A number of formulation dimensions and materials specifications are 
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implicated in the emulsification solvent evaporation method that influence the measured 
responses. These parameters include energy employed; aqueous phase volume; polymer 
and drug concentration in the organic phase, solvent volume and surfactant concentration. 
 
The aim of this study was to design and develop a nanoparticulate delivery system small 
enough to bypass the blood-brain barrier and one that can enhance cellular uptake and 
biodistribution of therapeutic agents without presenting cytotoxicity. L100 was the 
polymethacrylate chosen to prepare and optimise the nanospheres (in combination with 
PDLLA) as it gave the most desirable results of the anionic polymethacrylates in chapter 3. 
Amantadine-loaded nanospheres were prepared and bound with the chelating ligand 
diethylenetriaminepentaacetic acid (DTPA), a polyaminocarboxylic acid (Kontoghiorghes, 
1995) that is able to remove several ions including copper and zinc. Various processing 
parameters on particle size and the characteristics of the nanospheres were investigated. 
The processing parameters include polymer concentration in the organic phase, volume of 
solvent and the sonication time of the aqueous and organic phase. The drug used was 
amantadine, which is an antiviral drug that has anti-parkinsonian effects. 
The nanospheres were characterised by utilising techniques such as size and surface 
analysis; morphology analysis through transmission electron microscopy (TEM); FTIR 
spectroscopy; and in vitro drug release studies. 
 
4.2. Materials and Methods 
4.2.1. Materials  
Polymethacrylate (PMA): Methacrylic acid copolymer (Eudragit L100) was purchased from 
Degussa, RohmGmbH, Pharma Polymers (Germany). Poly(D,L-lactide) (PDLLA), 
Diethylenetriaminepentaacetic acid (DTPA), N-Hydroxysuccinimide (NHS), N,N’-
Dicyclohexylcarbodiimide (DCC) and amantadine hydrochloride were all purchased from 
Sigma-Aldrich (St Louis, MO, USA). Membrane filters (0.22µm) were purchased from 
Millipore® (Billerica, MA, USA). All other chemicals used in the experiments were of 
analytical grade and were used as purchased. 
4.2.2. Box-Behnken design optimisation for the preparation of amantadine-loaded 
nanospheres 
A three-factor, three-level Box-Behnken statistical design on MINITAB® (V14, State College, 
Pennsylvania, USA) was used to optimise the preparation of amantadine-loaded PDLLA-
PMA nanospheres. Upper and lower levels of three independent parameters that included; 
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ultrasonication time, solvent volume and amount of polymer (L100) were selected as they 
highly influenced the changes in the fabrication of the nanospheres with a constant quantity 
of PDLLA (40mg). The dependent responses were; particle size, zeta potential, drug 
entrapment efficiency and mean dissolution time (MDT). Fifteen formulations were 
generated from the Box-Behnken design (Table 4.1) and were prepared and tested. The 
results obtained were inserted into the MINITAB® design software which produced 
independent parameter values for the optimised formulation as well as the expected 
responses (Table 4.2). 
 
Table 4.1: 3-factor Box-Behnken experimental design for PDLLA-PMA nanosphere 
formulation. 
Formulation Eudragit L100 
(mg) 
Sonication 
time (min) 
Solvent 
volume (mL) 
1 210 20 15 
2 160 20 20 
3 210 30 20 
4 210 20 15 
5 210 20 15 
6 260 20 10 
7 260 10 15 
8 260 20 20 
9 160 10 15 
10 210 30 10 
11 160 20 10 
12 210 10 10 
13 210 10 20 
14 260 30 15 
15 160 30 15 
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Table 4.2: Responses for the Box-Behnken statistical design 
Response Objectives 
Particle size (nm) Minimise 
Zeta potential (mV) Minimise 
Drug entrapment efficiency (%) Maximise 
Mean dissolution time (hours) Minimise 
 
4.2.3. Preparation and optimisation of the amantadine-loaded Eudragit® nanospheres 
Nanospheres were prepared using the double-emulsion solvent evaporation technique 
utilizing sonication. Briefly, the internal aqueous phase was prepared by dissolving 100mg of 
amantadine in 1mL of deionised water. The organic phase was prepared by dissolving both 
polymers, PDLLA and Eudragit L100, in a solvent mixture of dichloromethane and isopropyl 
alcohol in a 1:1 ratio. The internal aqueous phase and organic phase were sonicated for 
3min at room temperature to form a primary emulsion. The external phase was prepared by 
dissolving span80 in phosphate buffer saline (PBS) to form a 0.025%
v
/v solution. The 
primary emulsion was then added drop-wise to the external aqueous phase followed by 
sonication to form nanospheres. The formed nanoemulsion was centrifuged at 1500rpm for 
20 minutes at room temperature to recover the nanospheres, washed twice with distilled 
water and thereafter lyophilized (Lanconco, Kansas City, MS, USA) for 24 hours.  
The effects of various processing parameters on particle size, drug entrapment and mean 
dissolution time were investigated. The processing parameters that had an effect on particle 
size were polymer concentration, volume of solvent and the time taken to apply an external 
energy (sonication). A 3-factor Box-Behnken design was employed to generate various 
amantadine-loaded PDLLA-PMA nanosphere formulations (Table 4.1). 
4.2.4. Determination of the stability of the optimised nanosphere emulsion 
The stability of the nanosphere emulsion was determined employing a Turbiscan Lab® 
(Turbiscan LabTM, Formulaction SA, L’Union, France) as described in section 3.2.5. Briefly, 
Poly-DL-lactide polymethacrylate nanosphere emulsion was poured into a flat bottomed 
boroscillated glass cell (27.5x70mm) up to a height of approximately 40mm then placed into 
70 
 
the Turbiscan Lab® instrument. Synchronous dual measurements were performed by the 
transmission detector (at 180°) that receives the light, which went through the sample, while 
the backscattering detector (at 45°) received the light scattered backward by the sample. 
The light source has pulsed infrared with a wavelength of 880nm. Measurements were 
performed at 25°C and the Turbiscan Lab® was configured to perform scans for 5 minutes, 
over a 55mm cell length from bottom to top acquiring transmission and backscattering data 
every 40 μm. Deviation in particle volume fraction on particle migration and the mean 
particle diameter attributable to coalescence resulted in variation in the magnitude of 
transmitted and back-scattered light. The measured amount of transmitted and 
backscattered light was then interpreted and used to describe the dispersion state (stability) 
of the emulsion. 
4.2.5. Determination of particle size distribution, zeta potential and polydispersity 
index 
The average size of the nanospheres was measured by dynamic light scattering (DLS) on a 
Zetasizer NanoZS instrument (Malvern Instruments, Worcestershire, UK) at 25°C, followed 
by the analysis of zeta potential and polydispersity index (PdI). Measurements were 
performed by firstly filtering the nanosphere suspension through a 0.22µm filter (Millipore, 
Billerica, USA) to remove any polymer agglomerates and using disposable cuvettes for each 
run (quartz cuvettes). Each test was performed in triplicate and the average value in each 
case was reported accordingly.    
4.2.6. Analysis of the surface morphology of the nanospheres 
Transmission electron microscopy (TEM) was used to examine the shape and size of the 
nanospheres. Samples were dispersed in PBS (pH 7.4) and a drop of the diluted sample 
placed on a carbon-coated copper grid and left to dry for 20 minutes. The copper grid was 
placed in the TEM and viewed at various magnifications at room temperature. 
4.2.7. Determination of the amantadine-loading capacity from the nanospheres 
In order to determine the drug entrapment efficiency of amantadine-loaded nanospheres, 
accurately weighed samples of each of the 15 formulations were resuspended in 10ml of 
phosphate buffer saline (PBS; pH 7.4) (at 37°C) accordingly. The samples were then 
centrifuged at 2500rpm for 30mins followed by a reaction of the supernatant with potassium 
permanganate for 15 minutes at room temperature. The absorbances of the resulting 
solutions were measured at 525nm by UV spectrophotometry (Lambda 25, UV/VIS 
Spectrometer, PerkinElmer®, Waltham, MA, USA) against a reagent blank and computed 
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from a standard linear curve of the drug in PBS to determine amantadine content.  Equation 
4.1 was used to compute the DEE. All tests were performed in triplicate. The theoretical 
amount of amantadine was considered as the proportional amount of amantadine in 10mg of 
nanospheres in reference to the loading dose. 
 
% DEE = Da 
              Dt      × 100,                                                                                                          Equation 4.1. 
 
where % DEE is the percentage of drug entrapped, Da is the actual drug quantity (mg) 
measured by UV spectrophotometry and Dt is the theoretical drug (mg) added to the 
formulation. 
4.2.8. In vitro drug release studies 
In vitro drug release studies were carried out for 72 hours using an orbital shaking incubator 
set at 25rpm. The amantadine-loaded nanospheres contained in dialysis tubing, were 
immersed in 50 mL phosphate buffer saline (PBS) at pH 7.4, 37°C in glass jars. At 
predetermined time intervals 2mL samples of the release media were removed and replaced 
with fresh buffer of the same volume to maintain sink conditions. It was reported that this 
method can only be used for the release of formulations with drug release times of greater 
than 1 hour. Samples were then centrifuged and the supernatant analysed by UV 
spectroscopy at a maximum wavelength of λ525, after leaving it to react with potassium 
permanganate reagent. Drug quantity was determined using a standard calibration curve. 
Dissolution profiles were produced from the amantadine released over 72 hours and these 
profiles were used to characterise in vitro amantadine release kinetics from the 
nanospheres. Mean dissolution time (MDT) was used to analyse the ability of the 
nanospheres to control amantadine release using equation 4.2 
 
     MDT = 
           
        
                                                                                         Equation 4.2. 
 
The dissolution efficiency (DE) of a pharmaceutical dosage form is defined as the area under 
the dissolution curve up to a certain time, t, expressed as a percentage of the area of the 
72 
 
rectangle described by 100% dissolution in the same time. It is represented in Figure 4.1, 
and can be calculated by the following equation: 
DE = 
      
 
 
        
 x 100%                                                                                        Equation 4.3. 
 
                 
where y is the drug percentage dissolved at time (t) 
 
                                      
Figure 4.1: Illustration of dissolution efficiency which is defined as the area under the 
dissolution curve up to a certain time (Costa et al., 2001) 
 
 
 DE (%) = 
  
 
 x 100                                                                                                Equation 4.4. 
 
where SA is the shaded area and R is the rectangle area (y100 x t). 
 
4.2.9. Analysis of chemical structure of nanospheres 
Amantadine-loaded and drug-free nanosphere samples were scanned at high resolution 
over wavenumbers ranging between 4,000 and 650 cm-1 on a Nicolet Impact 400D FTIR 
Spectrophotometer combined with Omnic FTIR research grade software (Nicolet 
Instruments Corp., Madison, WI, USA). The samples were compressed into 1x13mm disks 
using a Beckmann Hydraulic Press (Beckmann Instruments Inc., Fullerton, USA) to prepare 
them for analysis. 
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4.2.10. Thermal analysis using differential scanning calorimetry (DSC) 
The thermal properties of PDLLA, L100, amantadine and the amantadine-loaded 
nanospheres were analysed by DSC. The analysis was conducted on a differential scanning 
calorimeter (Mettler Toledo, DSC1, STARe System, Schwerzenback, Switzerland) which 
was dually calibrated for temperature and enthalpy using indium and zinc. All experiments 
were performed at a heating rate of 10°C min-1 under a dry nitrogen atmosphere (Afrox, 
Germiston, Gauteng, South Africa) which flowed at a rate of 200mLmin-1 acting as the purge 
gas in order to reduce sample oxidation. Samples were placed in 40μL aluminium pans and 
heated at various temperature ranges.  
The samples were then cooled down to -10°C at a rate of 20°C min-1. The midpoint melting 
point (Tm) which was used for characterisation was obtained from the melting point 
depression of the peaks generated on the experimental DSC curves when samples were 
heated. 
 
4.2.11. Surface modification of the nanospheres using DTPA 
Nanospheres were resuspended in 20ml of phosphate buffer saline (PBS; pH 7.4) and DCC 
was dissolved in 5ml of dichloromethane. The two solutions were mixed under magnetic 
stirring for 1 hour. The dichloromethane was removed by rotary evaporation (Rotavapor® 
RII, Büchi Labortechnik AG, Switzerland) maintained at 65°C for 1 hour. Simultaneously, 
NHS and DTPA were dissolved in PBS (pH 7.4) under magnetic stirring for 3 hours. The two 
solutions were then combined and stirred for a further 4 hours. The final solution was 
stabilised at 4°C before it was centrifuged and washed twice to remove unbound DTPA. 
4.2.12. Assessment of the conjugation efficiency of DTPA on the nanosphere surface 
The evaluation of the conjugation efficiency of DTPA on the surface of nanospheres was 
done using a UV spectrophotometer. The absorbance of the conjugated nanospheres in 
solution was read at λmax = 260nm against a blank sample of unmodified nanospheres and 
calculated using equation 4.5: 
 
Conjugation efficiency (%) =   Actual quantity of DTPA on nanospheres 
                                               
                                                     Theoretical quantity of DTPA employed                       Equation 4.5. 
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4.3. Results and Discussion 
 
4.3.1. Preparation and optimisation of the amantadine-loaded Eudragit® nanospheres 
Amantadine-loaded nanosphere formulations were obtained using the different preliminary 
variables predetermined by the 3-Factor Box-Behnken experimental design (Table 4.1). 
Organic solvents were chosen according to the solubility of the polymers. The double 
emulsion evaporation technique was used based on its advanced encapsulation of water 
soluble drugs in comparison to other incorporation methods (Dhanaraju et al., 2003; Ravi et 
al., 2008). Double emulsion solvent evaporation involved two steps where the polymer 
solution containing the drug was emulsified, which determined the size distribution of the 
nanospheres, followed by the solidifying of the nanospheres through solvent evaporation 
and polymer precipitation. The addition of the primary emulsion to the external aqueous 
phase resulted in an instant change of the solution into a turbid mixture, indicative of the 
spontaneous formation of nanospheres. 
The shear stress produced by the sonicator induced the breaking up of the polymer solution 
into nano-droplets while the addition of the span 80 in the external phase increased the 
stability of the formulations. Adding the primary emulsion intermittently and drop-wise into 
the external phase prevented aggregation of the polymers as well as assisted in producing 
smaller sizes of the nanospheres. Larger sizes were produced when formulations were 
prepared utilising parameters lying outside the predetermined limits. 
The subsequent responses obtained for the various formulations: the nanosphere size, zeta 
potential, amantadine entrapment and mean dissolution time were employed for the 
optimisation process. The results obtained from the experimental design (Table 4.3) were 
inserted into the MINITAB® software to yield ten potential optimised formulations and the 
selected, most suitable optimised formulation had a composite desirability (D), size 
desirability, zeta potential desirability and MDT desirability of 1.000. The most optimum 
parameters were those that displayed a desirability of 1.000 and those that had a desirability 
closer to 0.000 were considered the least optimum parameters. The optimal formulation had 
independent parameters; sonication time of 30.0 minutes, Eudragit L100 amount of 260.0 
mg and solvent volume of 20.0 mL which produced predicted nanosphere responses of; size 
of 79.03 nm, zeta potential of -27.24 mV, drug entrapment of 37.28 % and a MDT of 18.27 
hours (Figure 4.2). The correlation of the independent parameters; sonication time, solvent 
volume and amount of Eudragit L100 to the responses; nanosphere size, zeta potential, drug 
entrapment and MDT was represented as response mesh plots presented in Figure 4.3. 
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Figure 4.2: Optimisation plots displaying factor levels and desirability values for the 
optimised amantadine-loaded nanospheres 
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Table 4.3: Response data obtained for the 3-factor Box-Behnken experimental design 
PDLLA-PMA nanosphere formulations. 
Formulation Size 
(nm) 
Zeta Potential 
(mV) 
Drug Entrapment 
(%) 
MDT 
(hrs) 
F1 81.94 -24.7 35.84 21.07 
F2 104.4 -21.1 19.43 21.34 
F3 81.98 -26.4 33.31 20.12 
F4 69.08 -23.2 34.89 21.91 
F5 88.22 -27 35.48 19.33 
F6 99.99 -25.9 39.75 14.07 
F7 75.8 -25.9 39.29 22.5 
F8 78.4 -22 38.62 22.47 
F9 73.78 -27.1 19.45 12.71 
F10 101.2 -14.3 34.08 20.4 
F11 68.31 -26.5 19.56 19.54 
F12 76.32 -22.8 35.53 15.57 
F13 138.1 -23.7 32.97 21.79 
F14 112.8 -27.9 38.13 18.1 
F15 113.6 -29.2 19.48 21.94 
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Figure 4.3: Response mesh plots correlating dependent formulation parameters; 
nanosphere size, zeta potential (ZP), drug entrapment (DE) and MDT to their independent 
parameters; sonication time (ST), solvent volume (SV) and amount of Eudragit® L100. 
 
4.3.2. Effects of Formulation Variables on Measured Parameters 
Nanosphere size has an effect on drug loading, drug release, and ultimately targeted 
delivery of amantadine across the BBB.  Prepared formulations produced sizes of between 
68 and 113nm (Figure 4.4) which is small enough for cellular uptake considering vesicles 
between 100-150nm can be endocytosed at the site of action (Kim et al., 2007). The 
formulations displayed poly dispersity index (PdI) values of less than 0.5 which was an 
indication of a uniform nanosphere size distribution. The zeta potential values ranged from -
14.3mV to -29.2mV (Table 4.4). The increased zeta potential values indicate the high 
stability of the nanospheres by electrostatic repulsion forces and the net negative charge is 
as a result of the anionic PMA. The experimental design showed moderate entrapment 
efficiency of the nanospheres ranging from 19.43 to 39.75%. A large quantity of amantadine 
was still in solution after phase separation.  
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Figure 4.4: Size plot depicting the sizes of various PDLLA/PMA nanosphere formulations 
 
The assessment of the residual error is crucial in determining the effectiveness of an 
experimental design. Various residual plots were used for the evaluation of the design. It 
must be taken into consideration, however, that a small sample size (less than 50) was 
used. In such a case a histogram is not regarded as the best selection in the assessment of 
normality however, normal probability plot has a much higher level of sensitivity. Figure 4.5 
shows the different residual plots for the dependent formulation parameters. All the 
parameters produced points that roughly form a straight line in their normal probability plots 
i.e. all points are in close proximity to the straight line, signifying a normal distribution of 
residuals. Even distribution on either side of the zero line is apparent in the fitted residual 
versus fitted value plots. A bell-shaped histogram indicates normal distribution of data. None 
of the responses produced bell-shaped histograms which may suggest the presence of data 
points with large residuals. In the residuals versus the order of the data, there is regular 
oscillation on either side of the centre line representative of error terms that are not related 
with one another and are therefore independent.  
Dissolution studies indicated a controlled release profile of amantadine from the 
formulations.  Minimal drug was released at t = 0.5 for all 15 formulations (Figure 4.6). This 
initial release could be attributed to drug that has been adsorbed on the surface of the 
nanospheres followed by the release of the drug entrapped in the core of the nanospheres. 
After 24 hours about 50% of the drug was released from the nanospheres and the graphs 
show that there was prolonged drug release for over 72 hours. 
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a)  b)  
 c)  d)   
Figure 4.5: Residual plots of the data for MDT, particle size, zeta potential and drug entrapment for the nanosphere formulation 
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Figure 4.6: Drug release profiles of the 15 formulations in the experimental design 
(Standard Deviations (SD): ±0.2693; ±0.2622; ±0.2512; ±0.2566; ±0.2060; ±0.2195; 
±0.2434; ±0.2454; ±0.1971; ±0.2185; ±0.2545; ±0.1809; ±0.2132; ±0.1944; ±0.2085 
respectively) 
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4.3.3. Optimised formulation 
The optimised formulation had an average zeta size of 80.41nm (Figure 4.7), zeta potential 
of -27.7mV, drug entrapment of 50.92% and a Mean Dissolution Time (MDT) of 19.3 hours. 
All these values were exceedingly close to the values predicted (see Figure 4.2). This shows 
that the box-behnken design is excellent at predicting responses. Drug entrapment, 
however, had a noticeable improvement to the predicted value.  
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Figure 4.7: Drug release profile of the optimised nanosphere formulation (SD ±0.206) 
 
4.3.4.  Nanosphere emulsion stability 
The delta back scattering profile of the optimised nanosphere emulsion depicted in Figure 
4.8a shows that the nanosphere emulsion was largely stable. The middle and the bottom of 
the profile remained consistent which meant that the emulsion was stable over the test 
duration and no flocculation or coalescence occurred to the nanosphere emulsion during the 
entire time the experiment took place. There was, however, a small amount of local 
destabilisation which can be seen by the slight wavering in the delta backscattering signal at 
the top end of the glass cell.  
 
Figure 4.8b shows that between 32.4mm and 48.1mm (a section in the middle of the profile) 
backscattering in percentages verses time remained steady and further confirms that the 
nanosphere emulsion was stable. Figure 4.9 depicts the phase thickness of the clear phase 
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from middle to the beginning of the top profile. The emulsion slightly increases in thickness 
between 36.7mm and 52.5mm showing the minor destabilisation at the top profile. 
 
a)   
 
b)  
 
 
 
Figure 4.8: a) Delta backscattering (DeltaBS) for optimised amantadine-loaded PDLLA-L100 
nanospheres; b) Backscattering presented in percentage versus time: BS (t), at the following 
section on the cell: 32.4mm – 48.1mm 
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Figure 4.9: Delta H (t), which is the phase thickness from transmission (36.7mm – 52.5mm) 
 
4.3.5.  Differential scanning calorimetry of the drug and nanosphere components 
DSC thermograms of L100, PDLLA, amantadine and amantadine-loaded PDLLA-L100 
nanospheres are depicted in figure 4.10. L100 had an onset melting point at 196.66°C and 
an exothermic crystallization peak at 214.42°C (Figure 4.10a). PDLLA had a melting point 
represented by an endothermic peak maximum at 54.02°C as well as an exothermic 
crystallization peak at 58.18°C (Figure 4.10b). Amantadine, the study drug, had an 
endothermic peak with a melting point peak maximum at 320.53°C and an exothermic 
crystallization peak at 323.44°C (Figure 4.10c). The thermal DSC thermogram of 
amantadine-loaded PDLLA-L100 nanospheres (Figure 4.10d) confirmed that L100, PDLLA 
and amantadine were all present and contributed to the composition of the nanospheres. 
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a)                   b)  
c)                                             d)  
Figure 4.10: DSC thermograms of a) L100; b) PDLLA; c) amantadine and d) amantadine-loaded PDLLA-L100 nanosphere 
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4.3.6. Conjugation Efficiency of DTPA on the Surface of the Nanospheres 
The conjugation efficiency of the modified DTPA-bound nanospheres was determined using 
a NanoPhotometer™ spectrophotometer (Implen GmbH, Munich, Germany). Results 
showed a conjugation efficiency of 74%. This outcome shows that the method of conjugation 
is highly proficient and thus the modified DTPA-bound nanospheres are suitable for 
enhancing delivery of therapeutics into brain cells. 
The DTPA-bound nanospheres had a size of 105.6nm (Figure 4.11b), a PdI of 0.240 and 
zeta potential of -31.0mV. The results indicated that the DTPA-bound nanospheres provided 
a slight increase in the net negative charge for the zeta potential value and a comparative 
increase in particle size. Accordingly, the zeta potential of the modified nanospheres 
provided certainty that the synthesised nanospheres were physically stable. 
 
    a)  
   b)      
Figure 4.11: Comparison of the size distributions of a) the unmodified optimised 
nanospheres and b) DTPA-bound optimised nanospheres 
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4.3.7. Morphological Characterisation of the Modified Nanospheres 
 
TEM micrographs of modified DTPA-bound nanospheres are shown in Figure 4.12. TEM 
images revealed spherical and uniform unmodified nanospheres and modified nanospheres. 
In addition, the images show that the unmodified nanospheres and modified nanospheres 
synthesized were of a nano size range. DTPA was conjugated onto the nanospheres and 
was incorporated in the surface morphology. 
                 a)   
                 b)  
Figure 4.12: TEM images of the a) unmodified optimised nanospheres and b) DTPA-bound 
nanospheres 
 
 
4.3.8. Assessment of the Modified Nanosphere Chemical Structure Variations 
The qualitative features of infrared spectroscopy are one of the most powerful aspects of this 
varied and resourceful analytical technique. FTIR spectra were generated to characterize the 
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potential interactions of the nanospheres and DTPA. As clearly depicted in Figure 4.13, FTIR 
spectroscopy confirmed that there were molecular structural changes in the modified 
nanospheres compared to the unmodified nanospheres. The FTIR spectra of modified 
nanospheres displayed a characteristic bond formation at a wavenumber of 3321.09 cm-1 
which was assigned to –OH and –NH stretch due to the presence of the DTPA ligand. This 
peak was absent in FTIR spectra of the unmodified nanospheres. Results showed that there 
were interactions between the nanospheres and DTPA, which culminated in the formation of 
the new modified nanospheres. 
a)  
 
b)
Figure 4.13: FTIR spectra of (a) native DPTA and (b) unmodified nanospheres and modified 
DTPA-bound nanospheres  
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4.4. Concluding remarks 
Amantadine-loaded DTPA-bound PDLLA-L100 were successfully designed, characterised 
and optimised employing the randomised Box-Behnken statistical design. Desirability plots 
were used to elucidate the efficacy of the design. The prepared nanospheres had response 
values very close to those of the predicted values with a noticeable improvement in the drug 
entrapment efficiency. The double-emulsion solvent evaporation method was used which 
produced small, spherical and stable nanospheres. Dynamic light scattering, TEM and the 
backscattering profiles from the Turbiscan Lab® were used to confirm these results 
respectively. Dissolution studies implemented in PBS (pH 7.4) showed that minimal drug 
was released in the first 30 minutes of the study. Thereafter, there was prolonged drug 
release for over 72 hours. The nanospheres were also successfully conjugated to the 
chelating ligand DTPA with a conjugation efficiency of 74% and this was observed on FTIR 
spectra. 
Essentially, biocompatible nanospheres which are able to deliver amantadine over 72 hours, 
are small enough to be internalised by cells and are modified with a chelating ligand were 
effectively formulated with the aim to employ them in ALS. These nanospheres would benefit 
from being embedded in an implant that would further prolong the release of amantadine 
and ensure that the site of action is sufficiently exposed to the drug with vastly decreased 
dosing. Further studies incorporating these amantadine-loaded DTPA-bound nanospheres 
into a biocompatible thermosensitive hydrogel are presented in Chapter 5. The hydrogel is to 
serve as a carrier for the nanospheres and further control the release of the drug. 
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CHAPTER FIVE 
FORMULATION AND IN VITRO TESTING OF A THERMOSENSITIVE HYDROGEL AS 
A CARRIER FOR THE AMANTADINE-LOADED LIGAND-BOUND NANOSPHERES 
 
 
5.1. Introduction 
Implantable systems are valuable in biomedical applications such as regional tissue 
engineering for mechanical support as well as drug and cell delivery functions (Figure 5.1). 
These implants are beneficial in keeping patients compliant in their treatments. For example, 
in the treatment of patients with a mental illness, where cognitive impairment may affect 
compliance or in tuberculosis where a number of pills have to be taken over a long period, 
implants are advantageous. Implants that are designed to gradually release therapeutic 
agents over several weeks or months reduce the number of times patients must visit the 
hospital or the frequency medication needs to be administered. 
 
Therapeutically, implants could achieve increased levels of remedial agents at the 
implantation site. Specifically, injectable thermally responsive polymers with a lower critical 
solution temperature (LCST) below body temperature offer promising biomaterials for a 
variety of applications in the human body (Ma et al., 2010). Thermosensitive polymers are 
characterised by the presence of hydrophobic groups, such as methyl, ethyl, and propyl 
groups (Satish et al., 2006). Commonly, the LCST-based phase transition in these polymers 
occurs upon increased temperature in situ as a result of dehydration of polymer 
components, leading to the disintegration of polymers (Aseyev et al., 2010). Above LCST, 
hydrogen bonds (between amide groups in polymer and water molecules) are broken and 
water molecules are expelled from the polymer, resulting in precipitation of the polymer 
(Aseyev et al., 2010). A range of naturally derived and synthetic polymers displaying this 
characteristic and others have been employed and some can be seen in Table 5.1. Natural 
polymers consist of elastin-like peptides and polysaccharide derivatives, while notable 
synthetic polymers include those based on poly(Nisopropylacrylamide) (PNIPAAm), and 
amphiphilic block copolymers, often containing poly(ethylene glycol) (Schmaljohann, 2006). 
Not only are these thermoresponsive polymers used for implants or gels, but for various 
other delivery systems prepared in a variety of ways, achieving solidification in situ through 
mechanisms depending on the delivery system (Table 5.2). These delivery systems have 
distinctive challenges related to their development that are linked to drug stability, drug 
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release kinetics and the environment under which the system is delivered to the body (Hatefi 
and Amsden, 2002). 
 
Figure 5.1: Uses of in situ forming thermally responsive hydrogels (Moon et al., 2012) 
(http://pubs.rsc.org/en/content/articlelanding/2012/cs/c2cs35078e#!divAbstract) 
 
Table 5.1: Common natural polymers and synthetic monomers employed in hydrogel 
preparation (Ganji and Vasheghani-Farahani, 2009) 
Natural polymers Synthetic monomers/ polymers 
Chitosan 
 
Hydroxyethylmethacryate (HEMA) 
 
Alginate 
 
N-(2-Hydroxy propyl)methacrylate (HPMA) 
 
Fibrin 
 
N-Vinyl-2-pyrrolidone (NVP) 
 
Collagen 
 
N-Isopropylacrylamide (NIPAMM) 
 
Gelatin 
 
Vinyl acctate (VAc) 
 
Hyaluronic acid 
 
Acryolic acid (AA) 
 
Dextran Methacrylic acid (MAA) 
 
 Polyethylene glycol acrylate/methacrylate (IPEGA/PEGMA) 
 
 Polyethylene glycol diacrylate/dimethacrylate (PEGDA/PEGDMA) 
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Table 5.2: Biodegradable in situ solid forming delivery systems (Hatefi and Amsden, 2002) 
Delivery system 
 
Common problems Common components 
Thermoplastic paste 
 
 High temperature at the time of injection PLA, PLGA & PCL. Alcohols as initiator. 
In situ crosslinked systems 
 
 Stannous Octoate as catalyst. 
Thermosets  Unacceptable level of heat released 
during reaction 
 Burst in drug release 
 Toxicity of un-reacted monomers 
Oligomers of PLA, PDLLA & PCL, Polyols as 
initiator and peroxides as curing agent. 
Photocrosslinked gels  Shrinkage and brittleness of the polymer 
due to high degree of crosslinking 
PGA, PLA, PCL & PEG, initiators such as eosin 
dye, light source (e.g., UV or laser) 
Ion mediated gelation  Low shelf life 
 Burst in drug release 
 Long degradation time 
alginate with Ca
2+
 as gelling agent 
In situ polymer precipitation  Burst in drug release PDLLA, PCL & PLA. Solvents such as DMSO or 
NMP. 
Solvent-removal  
 
 Burst in drug release  
Precipitation 
 
 Application of organic solvents  
Thermally induced sol-gel transition 
 
 Stability of oils and purity of waxes NIPAAM, PEG, PLA, PLGA & Chitosan, Pluronics 
Organogels  Lack of toxicity data 
 Phase separation 
Oils such as peanut oil & Labrafil, waxes (e.g., 
Beeswax & Pericerol). 
PLA = Polylactic acid; PLGA = Poly(lactic-co-glycolic acid); PCL = poly(e-caprolactone); PDLLA = poly(D,L-lactide); PGA =  Polyglycolic acid; PEG = 
poly(ethylene glycol); DMSO = dimethyl sulfoxide; NMP = N-methyl-2-pyrrolidone 
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Implants that form in situ exist as solutions at room conditions and transform into a gel like 
phase when in contact with a particular stimulus. There are various stimuli which may be 
ionic or chemical cross-linking or photopolymerisation or a local environmental stimulus such 
as pH, ionic strength or as mentioned previously, temperature. Temperature sensitive 
polymers can exhibit one of two behaviours; they either display upper critical solution 
temperature (UCST) or a lower critical solution temperature (LCST) (Zhang et al., 2004; 
Aseyev et al., 2011). Polymers, which become insoluble upon heating, have a LCST and 
those that become soluble upon heating, have an upper critical solution temperature. An 
observable advantage of thermal gelation is its nearly instantaneous gelation subsequent to 
the polymer reaching the LCST.  
Gelation can either be physical or chemical (Gupta et al., 2006). Physical gels can be further 
classified as strong physical gels and weak physical gels (An et al., 2010). Strong physical 
gels possess strong physical bonds between polymer chains and are permanent at a given 
set of experimental conditions. Consequently, strong physical gels are equivalent to 
chemical gels. Examples of strong physical bonds are lamellar microcrystals, glassy nodules 
or double and triple helices. Weak physical gels have fluid networks formed from transitory 
links between chains. These links have finite lifetimes, splitting and being repaired constantly 
(Rubinstein and Dobrynin, 1997). Examples of weak physical bonds are hydrogen bond, 
block copolymer micelles, and ionic associations (Rubinstein and Dobrynin, 1999). On the 
other hand, chemical gelation involves formation of covalent bonds and always results in a 
strong gel. The three main chemical gelation processes include condensation, vulcanisation, 
and addition polymerisation (Gulrez et al., 2011). 
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Figure 5.2: Classification of gelation mechanism and relevant examples (Gulrez et al., 
2011).  
(http://www.intechopen.com/books/progress-in-molecular-and-environmental-bioengineering-from-
analysis-and-modeling-to-technology-applications/hydrogels-methods-of-preparation-characterisation-
and-applications) 
 
5.1.2. Viscoelasticity 
Viscoelastic materials are materials that exhibit both viscous and elastic characteristics when 
external forces are applied to them at different strain rates and temperatures (Ozkaya et al., 
2012). These materials resist shear flow and strain linearly with time when a stress is 
applied. This means a viscoelastic material will return to its original shape after any force 
that transformed its structure has been withdrawn (i.e., it will display an elastic reaction 
(Banks et al., 2010)) even though it will take time to do so (i.e., it will have a viscous 
component to the reaction). There are three ways in which a material can react in response 
to external forces in a physically stressful setting. It can add the load directly onto the forces 
that hold the essential atoms or molecules together, as occurs in simple crystalline (including 
polymeric crystalline) and ceramic materials – such materials are classically extremely firm; 
or it can transfer the energy into large modifications in shape (the main mechanism in 
noncrystalline polymers) and flow away from the force to deform either semi-permanently (as 
with viscoelastic materials) or permanently (as with plastic materials). 
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Hydrogels are viscoelastic materials as they exhibit both elastic and liquid characteristics. 
For elastic materials, Hooke’s Law of Elasticity (Figure 5.3) states that the force needed to 
extend or compress a spring by some distance is proportional to that distance. Hooke’s Law 
is used to describe the flow properties of a material with elastic characteristics and the term 
shear modulus (G) is used to relate the relationship between the shear stress (τ) and the 
deformation (γ) (Equation 3.2). Liquids are defined by Newton’s Law of Viscosity (Equation 
3.3) whereby the shear stress (τ) is proportional to the shear rate of the liquid (
  
  
). 
 
 
τ = Gγ                                                                                                         Equation 5.1 
 
τ = η 
  
  
                                                                                                       Equation 5.2 
 
 
                 
Figure 5.3: Illustration of Hooke’s Law showing the relationship between force and 
distance when applied to a spring. This can be expressed mathematically as F= -kX, 
where F is the force applied to the spring (either in the form of strain or stress); X is 
the displacement of the spring, with a negative value demonstrating the 
displacement of the spring once it is stretched; and k is the spring constant and 
details just how stiff it is (What is Hooke’s Law,  2015).  
(http://www.universetoday.com/) 
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Oscillatory rheology is required for the characterisation of hydrogels. The fundamental 
principle of an oscillatory rheometer is to generate a sinusoidal shear deformity in the 
sample and compute the resultant stress response; the time scale examined is determined 
by the frequency of oscillation, ω, of the shear deformation (Oscillatory rheometer, 2015). As 
shown in Figure 5.4 the application of a sinusoidal strain results in different resultant stress 
patterns in Hookean solids, Newtonian fluids and a viscoelastic solid. The viscoelastic solid 
shows a phase shift that lies between the phase shift of 0 for an elastic solid and 
 
 
 for a 
viscous fluid (Banks et al., 2010). 
 
 
             
 
Figure 5.4: Schematic representation of dynamic mechanical test instrument and 
relationship between stress and strain of completely elastic solid (Hookean solid) (A), 
viscoelastic material (B) and completely viscous liquid (Newtonian fluid) (C) with sinusoidally 
varying stress (Murata, 2012). 
(http://www.intechopen.com/books/polymerization/rheology-theory-and-application-to-biomaterials) 
 
In Figure 5.4, E' and E" are used as symbols for the elastic modulus component or storage 
modulus and loss modulus respectively instead of the commonly used G' and G". Equation 
5.3 is used to determine the total resistance of the sample to oscillatory shear which is 
represented by the complex modulus, G. The complex viscosity (η’) is the flow resistance of 
the sample and is determined using Equation 5.4 and Equation 5.5. 
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G = G' + iG" = (G'2 + G"2) ½                                                                                                                   Equation 5.3 
 
tan δ = 
  
  
                                                                                                            Equation 5.4 
 
η' = 
 
 
                                                                                                                    Equation 5.5 
 
where δ is the phase angle, η’ is the complex viscosity and ω is the angular frequency. 
5.2. Materials and methods 
5.2.1. Materials 
N-vinylcaprolactam (VCL), ε-Caprolactone and 2,2’-Azobis (2 methyl-propionitrile) (AIBN) 
were all purchased from Sigma-Aldich Inc., (St Louis, MO, USA). All other chemicals used in 
the experiments were of analytical grade and were used as purchased. 
5.2.2. Preparation of the thermosensitive hydrogel 
Several techniques have been reported for the synthesis of hydrogels. These include, firstly, 
an approach comprising copolymerization or cross-linking of co-monomers employing 
multifunctional co-monomer, which plays the role of a cross-linking agent. The 
polymerisation reaction is triggered by a chemical initiator. This form of hydrogel synthesis 
can be sub-divided into solution polymerisation and suspension polymerisation. The second 
technique entails the cross-linking of linear polymers by irradiation or by chemical 
compounds. The monomers used in the preparation of the ionic polymer network usually 
contain a group that is able to go through a substitution reaction after the polymerisation is 
completed. This leads to fabricated hydrogels enclosing weak acidic groups like carboxylic 
acids, weak basic groups like substituted amines, or strong acidic and basic group like 
sulfonic acids, and quaternary ammonium compounds. Some of the frequently used cross-
linking agents include N, N'-methylenebisacrylamide, divinyl benzene, and ethylene glycol 
dimethacrylate. (Satish et al., 2006) 
For this study, solution polymerisation was used. N-vinylcaprolactam and ε-Caprolactone 
were the co-monomers and AIBN was the cross-linker. Briefly, 2.5g of N-vinylcaprolactam 
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(VCL) and 0.2ml of ε-Caprolactone were dissolved in 20ml of isopropanol. The reaction 
mixture was flushed with nitrogen for 30 minutes. The solution was then dissolved in distilled 
water and the isopropyl alcohol removed by rotary evaporation. 0.2ml of AIBN was added to 
the remaining solution followed by overnight incubation in a sealed vessel at 60°C to form a 
sol. This reaction is depicted in Figure 5.5. 
 
Figure 5.5: Reaction scheme for solution polymerisation of the hydrogel 
5.2.3. Establishing the gelation temperature of the polymeric formulations employing 
oscillatory rheology  
Investigating the flow properties was important to this study as it is central to the 
mechanisms by which the hydrogel functions. At room temperature the hydrogel remains in 
the liquid state to allow delivery through injection and as the temperature increases so does 
the thickness of the gel until it forms a solid-like structure. In order to characterise and 
analyse the flow behaviour and determine the gelation temperature of the hydrogel, rheology 
studies were conducted using a Haake Modular Advanced Rheometer System 
(ThermoFisher Scientific, Germany).  
5.2.3.1. Determination of the viscoelastic region of the thermosensitive hydrogel 
  
Viscoelastic solids should be tested for their properties within the viscoelastic region. In 
order to determine the viscoelastic region of the hydrogel formulation, the sample was 
placed on the lower plate of the rheometer and the yield stress of the formulation was first 
determined, as this is the point at which a minimum critical shear stress is exceeded and 
therefore the point at which a viscoelastic substance begins to flow. Stress sweeps at 
0.01Hz, 1Hz and 10Hz were then conducted ensuring that the minimum strain applied was 
less than the yield stress value obtained. The stress sweep plots were then analysed and 
the plateau or linear viscoelastic region where both G' (storage modulus) and G'' (loss 
modulus) were independent of the stress amplitude, was used as the viscoelastic region. 
The first point of deviation from the plateau and the frequency at which it occurred was used 
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for subsequent temperature ramping tests. The yield stress was also determined, which is 
the amount of force needed to be applied for a sample to change its formation. For instance, 
some gels remain in their solid form until a force is applied where they then change to liquid. 
5.2.3.2. Determination of the gelation temperature of the hydrogel  
In order to determine the lower critical solution temperature (LCST) and hence the gelation 
temperature of the hydrogel formulation, the temperature of the sample was ramped from 
10-40˚C at a rate of 0.25˚C/min while applying the predetermined stress obtained from the 
stress sweeps previously described, at the frequency observed in that test. The gelation 
temperature was determined as the temperature at which the cross-over of G' and G'' 
occurred i.e., the point at which the formulation was no longer acting as a liquid (G'') but the 
solid phase (G') was dominating.  
 
5.2.4. Chemical structure analysis of the thermosensitive hydrogel employing Fourier 
transform infrared spectroscopy 
FTIR spectroscopy was performed on the polymers used to formulate the hydrogel as well 
as the hydrogel in its liquid and sol state in order to characterize the potential interaction 
between the polymers as well as the effect temperature has on the bonds in the hydrogel. 
Samples were compressed into 1x13mm disks using a Beckmann Hydraulic Press 
(Beckman Instruments Inc., Fullerton, USA), and then analyzed at high resolution with wave 
numbers ranging from 4,000–650 cm−1 on a Nicolet Impact 400D FTIR Spectrophotometer 
coupled with Omnic FTIR research grade software (Nicolet Instrument Corp., Madison, WI, 
USA). 
 
5.2.5. Morphological characterisation by scanning electron microscopy of a 
lyophilised sample of the thermosensitive hydrogel 
A lyophilised sample of the thermosensitive hydrogel was mounted on a specimen stub and 
gold coated using a SPI-ModuleTM sputter coater (SPI Supplies, STRUCTURE PROBE 
INC, West Chester, Pennsylvania, USA) and then observed at various magnifications under 
a scanning electron microscope (SEM) (PHENOMTM Desktop SEM, FEI Company, Oregon, 
USA) operated at 10KV in the electron imaging mode. 
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5.2.6. Preparation of the amantadine-loaded DTPA bound nanospheres carried by the 
thermosensitive hydrogel 
A homogenous solution was formed by blending the previously prepared amantadine-loaded 
DTPA-bound nanospheres with the thermosensitive hydrogel. The NVL/ε-Cap hydrogel was 
completely dissolved in water at a certain temperature followed by slightly heating it to form 
a sol. The nanosphere suspension was then mixed with the hydrogel to form a homogenous 
solution. 
 
5.2.7. In vitro drug release behaviour of amantadine from the thermosensitive 
hydrogel 
In vitro drug release studies to determine the release behaviour of amantadine from the 
prepared drug delivery system were carried out for 72 hours using an orbital shaking 
incubator set at 25rpm. The nanosphere-hydrogel composite was placed in dialysis tubing 
and immersed in phosphate buffer saline (PBS) at pH 7.4, 37°C in a glass jar. At 
predetermined time intervals 2ml samples of the release media were removed and replaced 
with fresh buffer of the same volume to maintain sink conditions. It was reported that this 
method can only be used for the release of formulations with drug release times of greater 
than 1 hour. Samples were then centrifuged and the supernatant analysed by UV 
spectroscopy at a maximum wavelength of λ525, after leaving it to react with potassium 
permanganate reagent. Drug quantity was determined using a standard calibration curve. 
Dissolution profiles were produced from the amantadine released over 72 hours and these 
profiles were used to characterise in vitro amantadine release kinetics from the nanosphere-
hydrogel composite. Mean dissolution time (MDT) was used to analyse the ability of the 
nanosphere-hydrogel composite to control amantadine release. 
5.3. Results and Discussion 
5.3.1. Rheological analysis of the thermosensitive hydrogel 
Rheology studies were performed on the hydrogel. Stress sweep was conducted at 0.1Hz to 
determine the linear viscoelastic region. This is the region where the viscoelastic properties 
observed are independent of imposed stress or strain levels. At the point where the graph 
plunges, is where the hydrogel breaks (Figure 5.6a). Yield stress (Figure 5.6b) is the amount 
of force required for the deformation of the hydrogel i.e. stretch from its solid phase until the 
yield point where it will start flowing. Studies showed that 4.558 Pa was the yield stress 
required for the hydrogel to flow. The irregular section of the graph (in blue) is background 
noise. 
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a)  
b)  
Figure 5.6: a) Rheological profile illustrating the stress sweep of the hydrogel; b) 
Rheological profile illustrating the yield stress of the hydrogel 
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The formulation displayed the characteristic pattern of a thermosensitive system with a 
Lower Critical Solution Temperature (LCST). As clearly illustrated in Figure 5.7, the point at 
which the storage and loss modulus crossover (dark green vertical line) was considered the 
gelation temperature (T˚g) for the formulation. The storage modulus (G′) of a viscoelastic 
solid is described as the point where the hydrogel exhibits solid properties or the elastic 
energy storage properties which signify that the removal of the deformational force will result 
in the hydrogel returning to its original form. Conversely, the loss modulus (G′′) describes the 
nature of the viscoelastic solid when it exhibits liquid characteristics. At the point at which the 
storage modulus exceeded the loss modulus, the formulation was therefore, exhibiting more 
solid properties than it was exhibiting liquid properties.  
 
Initially, G" is larger than G', which is expected since the sample was still in liquid state 
where viscous properties dominate, and therefore most of the energy is lost as viscous heat. 
As the solution starts to gel and a cross-linked network is formed, both G' and G" begin to 
increase; however, the rate of increase of G' is much higher than that of G" due to the elastic 
properties of the gelling hydrogel taking over and beginning to dominate. As a result, there is 
a crossover point where G' becomes larger than G". The temperature required for this 
crossover to occur is referred to as the gelation temperature for the solution, which was 
18.45 °C. This was much lower than expected and therefore the formulation had to be stored 
in the fridge to prevent gelation when handled normally. At room temperature the hydrogel 
was slightly thick and this thickness increased with increased temperature. This showed that 
the gel would certainly form a solid implant when inside the body. 
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Figure 5.7: Rheology profile of the temperature gelation. The dark green vertical line is 
illustrating the point at which the storage modulus (G′) and the loss modulus (G′′) crossover 
which is considered the gelation temperature (18.45°C) 
5.3.2. Chemical structure analysis of the thermosensitive hydrogel employing Fourier 
transform infrared spectroscopy  
FTIR was used to determine the chemical structure of the two polymers used to formulate 
the hydrogel as well as the hydrogel in its liquid and sol state. The FTIR shows that the two 
polymers formed new bonds in the formation of the hydrogel (Figure 5.8). A strong 
absorption peak (~1600cm-1) was observed on both the liquid and sol hydrogel spectrum 
which may have been contributed to by the strong stretching vibrations of the amide I band 
in N-Vinylcaprolactam. An ester linkage (~ 1700 cm-1) can aslo be observed on the hydrogel 
spectra which is typical of ε-caprolactone and thus may be due to its presence. The 
stretching vibration peak observed at ~3300 cm−1 in both hydrogel states may have been 
due to the N-H stretching vibration in N-Vinylcaprolactam. Results also indicate that there is 
a slight change in the bonds present in the hydrogel when it transitioned from liquid to sol 
state. Weak physical bonds are driven by intermolecular forces that can be created and 
broken over experimental time frames such as hydrogen bonding or van der Waals forces. 
Hydrogel polymer networks depend on chemical bonds for structure and physical bonds to 
facilitate volume-phase transition (Mah and Ghosh, 2013). Weak physical bonds that are 
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formed or broken through a phase transition are a collective consequence of supportive 
polymer-polymer interactions and polymer-solvent interactions. A phase transition then 
becomes a balance between repulsive forces that decrease polymer-polymer interactions 
and progress to swell the gel and attractive forces that decrease the polymer-solvent 
interactions and progress to disintegrate the gel.  
With regards to polymer-polymer interactions, attractive forces are hydrophobic interactions 
and van der Waals interactions while electrostatic interactions and hydrogen bonding may 
act as both attractive and repulsive forces depending on the environmental conditions.  
 
 
 
Figure 5.8: FTIR spectra of N-Vinylcaprolactam, ε-caprolactone, liquid hydrogel and sol 
hydrogel respectively. 
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5.3.3. Morphological characterisation by scanning electron microscopy of a 
lyophilised sample of the thermosensitive hydrogel 
Scanning electron micrographs of the thermosensitive hydrogel revealed the surface 
morphology and architectural integrity of the lyophilised structure as depicted in Figure 5.9. 
Figure 5.9a depicts a porous membranous scaffold with thin undefined smooth surfaces. The 
pores appear large and widespread across the surface of the scaffold. Another view of the 
hydrogel, however, shows a multidirectional membranous scaffold with some smooth 
surfaces and pores. This view depicts the hydrogel with uneven sheets embedded with a few 
pores. These two views of the hydrogel show that the scaffold did not have a homogenous 
morphology throughout its composition. 
 
            a)                                       
                 b)  
Figure 5.9: SEM images of the lyophilised thermosensitive hydrogel 
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5.3.4. In vitro drug release behaviour 
Release behaviour of amantadine from amantadine-loaded nanospheres was first 
investigated in chapter 4. In section 4.3.5 it was reported that amantadine could be released 
from the optimised nanospheres over a sustained period. The in vitro release profile of 
amantadine from the nanosphere-hydrogel composite was further examined, which is 
presented in Figure 5.10. Amantadine was released from the nanosphere-hydrogel 
composite in a sustained manner over an extended period. The hydrogel gradually released 
the nanospheres as it degraded followed by the release of the drug by the nanospheres. 
This resulted in the drug being released at a slower rate than when released soley by the 
nanospheres (without the hydrogel). This delay of drug release indicates the potential 
applicability of the nanosphere-hydrogel composite to minimise the exposure of tissues to 
the drug while increasing the accumulation of therapeutic drug in the focus area. 
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Figure 5.10: Comparison of amantadine released from nanospheres and nanosphere-
hydrogel composite with standard deviations of ±7.9481e-3 and ±0.2060 respectively. The 
hydrogel gradually released the nanospheres as it degraded followed by the release of the 
drug by the nanospheres. This resulted in the drug being released at a slower rate than 
when released soley by the nanospheres (without the hydrogel). 
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5.4. Concluding remarks 
A thermosensitive hydrogel formulation was prepared employing solution polymerisation and 
tested using oscillatory rheology and FTIR. The formulation displayed typical 
thermoresponsive behaviour with a Lower Critical Solution Temperature (LCST) when tested 
for its gelation temperature. FTIR spectra showed the blending of the two polymers to form 
the hydrogel. It was also revealed that there was a minor alteration in the bonds present in 
the hydrogel when it transitioned from liquid to sol state due to weak physical bonds. SEM 
showed that the hydrogel did not have a uniform morphology throughout its composition. 
 
The hydrogel formulation was blended with the previously prepared amantadine-loaded 
DTPA-bound nanospheres to form a homogenous solution. The nanosphere-hydrogel 
composite was tested for drug release. The hydrogel was able to greatly decrease the rate 
of release of amantadine and proved to be an efficient carrier of the amantadine-loaded 
nanospheres. 
 
In order to evaluate the safety of the composite system, the hydrogel formulation, the 
nanospheres and the nanosphere-hydrogel composite with their components would need to 
be tested for possible cytotoxicity. Chapter 6 describes the toxicity studies performed on 
motor neuron cells (NSC-34). In addition, cell uptake studies were undertaken to confirm the 
efficacy of the chelating ligand, DTPA, in increasing nanosphere internalisation by NSC-34 
cells. 
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CHAPTER SIX 
IN VITRO TESTING OF THE THERMOSENSITIVE HYDROGEL AND DTPA-BOUND 
NANOSPHERES ON A MOTOR NEURON CELL LINE 
6.1. Introduction 
Extensive research has been carried out to develop and investigate in vitro models of 
neurotoxicity. Organotypic and dissociated embryonic tissue are some of the tissues 
included in primary culture models. Primary culture is valuable because the cells mature 
morphologically and physiologically ultimately to resemble the cells naturally growing in the 
body. However, the disadvantage of primary culture is that these neurons require several 
days in culture to develop and subsequently serial passage is not viable. Various tumour cell 
lines have also been investigated. Nonetheless, despite the fact that these cells are 
exceedingly more expedient than primary culture, their extrapolative capacity of neurotoxicity 
is dependent on whether or not those cells express the applicable target for particular 
neurotoxic agents. Consequently, in an effort to produce cells that not only preserve 
neuronal properties but also proliferate, primary neurons have been fused with tumour lines 
(Cellutions Biosystems Inc, 2014). 
NSC-34 is a hybrid cell line that was formed with this technique, where motor neuron 
enriched, embryonic mouse spinal cord cells were merged with mouse neuroblastoma. 
Cultures contain two populations of cells: Undifferentiated cells with short neurites and 
almost no branches, and differentiated cells with long branching processes (Figure 6.1). 
(Maier et al., 2013)  These cells encompass many properties of motor neurons, including 
choline acetyltransferase, acetylcholine synthesis, storage and release and neurofilament 
proteins (Matusica et al., 2008). 
NSC-34 cells have been examined following exposure of cultures to a range of chemicals 
known to be neurotoxic to motor neurons. NSC-34 cells react to agents that have an effect 
on voltage-gated ion channels, cytoskeletal organisation and axonal transport. The 
sensitivity of action potential production to various ion channel blockers is similar to that in 
primary motor neurons in culture. Therefore these immortalised motor neuron-like cells have 
utility as a model for the investigation of neurotoxicity. 
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Figure 6.1 Differentiation-related alterations in murine neuronal cells, NSC-34. (A) 
NSC-34 contains small cells derived from mouse motor neurons and large 
multinucleated cells derived from mouse neuroblastoma. (B) Differentiated NSC-34. 
Small cells with extended neuronal processes. (Cellutions Biosystems Inc, 2014) 
(http://www.cellutionsbiosystems.com/) 
 
Cytotoxicity experiments measure the degree to which a compound is toxic to cells, possibly 
resulting in cell death. In vitro cytotoxic testing methods include the 3–(4,5–dimethylthiazol-
2-yl)–2,5–diphenyltetrazolium bromide (MTT), trypan blue (TB), sulforhodamine B (SRB) and 
(4-[3-(2-methoxy-4-nitrophenyl)-2-(4-nitrophenyl)-2H-5-tetrazolio]-1,3-benzene disulfonate 
sodium salt) (WST) assays and clonogenic assays (Grunert et al., 2011). These tests are 
vital in the research and development process and, within the context of the current study, 
allows for cytotoxicity levels to be evaluated prior to in vivo studies. 
 
An MTT assay, which is the chosen method for this study, is a colourimetric assay which 
provides a quantity of cell viability by supplying a measure of the proliferation of the cells 
(Riss et al., 2013). The tetrazolium salt, MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide) is added to the cells followed by a reduction to a purple 
formazan in the mitochondria of living cells (Figure 6.2). Dimethyl sulfoxide (solubilisation 
solution) is then added to the cells to dissolve the product formed by formazan which 
subsequently results in a coloured solution. Evaluation of the treated cells and the untreated 
control wells provides an indication of the cell viability. Treated cells that generate higher 
absorbances than the control cells signify enhanced proliferation of the cells and lower 
absorbance values signify a decline in cell growth. 
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Figure 6.2. Yellow tertrazolium (MTT) is reduced to purple formazan crystals by 
mitochondrial reductase enzymes. 
Another experiment important to this study is the testing of the uptake of the nanospheres by 
the motor neuron cells. The nanospheres were conjugated to diethylenetriamine penta-
acetic acid (DTPA), a chelating ligand that also increases cell uptake of nanoparticles. 
Vranic and co-workers investigated the mechanisms through which nanoparticles are taken 
up by cells. To determine whether cell uptake of nanoparticles is a passive or an active 
process, they depleted the energy of cells employing sodium azide (NaN3) which has been 
shown to inhibit the respiratory chain in mitochondria, consequently resulting in the 
impairment of the generation of ATP in the cell leading to the impairment of the uptake of 
active ATP. Sodium azide hindered the uptake of 50 nm-FITC SiO2 nanoparticles up to 
76%. They then compared the inhibition of uptake by NaN3 to the inhibition at 4°C that 
prevents not only active uptake but also the passive uptake by increasing the rigidity of the 
plasma membrane. At 4°C the percentage of inhibition was higher (85%) than for the cells 
treated with NaN3 (76%), suggesting that some 50 nmFITC-SiO2 nanoparticles may enter by 
passive diffusion. This was verified by confocal microscopy revealing that nanoparticles were 
on the cell surface as well as inside the cells subsequent to treatment with sodium azide 
compared to treatment at 4°C. The uptake of nanoparticles by a non endocytic pathway was 
already proposed and nanoparticles have been observed in red blood cells that lack 
endocytic properties. This passive uptake by red blood cells has been shown to involve 
adsorption of nanoparticles on the cell surface and strong local membrane deformations 
leading to uptake. 
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Ligands or antibodies have shown to further increase the uptake of nanoparticles by cells. 
Additionally, the size and shape of the nanoparticles play a role in the quantity of 
nanoparticles internalised by the cells. 
6.2. Materials and Methods 
6.2.1. Materials 
NSC-34 cells were obtained from Cedarlane Laboratories (Burlington, Ontario, Canada). 
Fetal bovine serum (FBS) and Penicillin-Streptomycin (Pen-Strep) were purchased from 
Highveld Biological (Modderfontien, South Africa). Dulbelccos Minimum Essential Medium 
(DMEM) Trypan Blue Solution (0.4%), MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide), Fluorescein isothiocyanate (FITC) and dimethyl sulphoxide 
(DMSO) were purchased from Sigma-Aldrich (St. Louise, MO, USA).  
6.2.1. Methods 
6.2.2.1. Aseptic technique 
  
Aseptic techniques were employed continuously in the culturing of cells. Briefly all surfaces 
of the horizontal laminar flow unit (Labotec, Midrand, South Africa) were wiped with 70% 
ethanol prior to experiments with cells. Laminar flow units are checked and certified twice a 
year. Gloves were worn at all times and were regularly sanitised with ethanol and when 
leaving the laminar flow unit. Laboratory coats and face masks were worn at all times in the 
cell culture room. All tissue culture bottles and flasks were sanitised with 70% alcohol before 
placing them in the unit and were flamed on opening and closing. All used disposable flasks, 
pipettes and culture equipment were incinerated, and all non-disposable items were treated 
with bleach for 2 hours before being discarded to the drain with profuse amounts of water. 
Cell medium was periodically tested for contamination by incubating media at 37˚C for 24 
hours. 
6.2.2.2. Culturing of cells 
  
NSC-34 cell line was grown using DMEM (with 4500 mg/L glucose, L-glutamine (0.584 g/L), 
sodium bicarbonate (3.7 g/L) without sodium pyruvate) supplemented with 10% fetal bovine 
serum and 0.25% Pen-Strep in a 25cm3 flask. When cells had reached confluency (~ 80%), 
media in the culture flask was discarded and 2 mL Trypsin-EDTA was added to each flask 
and the flasks were placed in the incubator for 3-4mins. When cells had detached, 3 mL of 
fresh media was added and the entire volume was centrifuged at 1000rpm for 3 minutes. 
The supernatant was discarded and the cell pellet was resuspended in 8 mL of fresh media 
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and plated into two flasks. When required, cells were frozen in a mixture of 60% growth 
medium and 30% FBS supplemented with 10% sterile dimethylsulfoxide (DMSO) at -80°C in 
vials overnight. The vials were then transferred and stored in liquid nitrogen. 
6.2.2.3. Cell counting using the trypan blue exclusion assay and a haemocytometer 
  
Following trypsination as described in Section 6.2.2.2., and the discarding of the 
supernatant, the cell pellet was resupended in 3mL of fresh media. The number of cells per 
mL of media was then determined using the trypan blue exclusion assay. Briefly, the cell 
suspension (10μL) was added to 20μL of trypan blue. A disposable chamber from a 
haemocytometer was then filled and its contents examined using light microscopy (Olympus 
CKS microscope, Olympus, Japan). The haemocytometer allowed the counting of the cells. 
Trypan blue was taken up by dead cells only and consequently by counting stained cells as 
well as unstained cells allowed the estimation of dead cells in the sample. Only samples that 
showed viability of greater than 95% were utilised in subsequent testing.  
6.2.2.4. Controls 
 
Positive and negative controls were used during the testing of samples. Table 6.1 
summarises the types of controls used and the rationale for the addition. 
Table 6.1 Summary of the controls used in the study 
Type of control Method Value in the study 
Positive  Standard solution of 
amantadine added to cells 
 
Assessment of susceptibility 
of the cells to amantadine  
Negative  1. Cells grow without the 
addition of other material 
 
To establish the viability of 
the cells and confirm that the 
tested material is responsible 
for any transformation of the 
cells  
 
 2. Incubation of blank 
medium with no cells  
To verify that the media is 
uncontaminated  
 
6.2.2.5. MTT assay  
 
6.2.2.5.1. Preparation of the MTT solution  
 
A 0.5%w/v of MTT was prepared as follows: 5g of MTT was added to 1 L of phosphate 
buffered saline, pH 7.4. The solution was filtered through 0.22μm filters and stored in the 
fridge (4˚C) in a foil covered flask until further use. 
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6.2.2.5.2. Determination of the effects of amantadine, polymers, nanospheres, 
hydrogel and the nanosphere-hydrogel composite on NSC-34 cells using the MTT 
assay  
 
6.2.2.5.2.1. Preparation of test samples  
 
The total amount of solution in all wells typically has to be 100µL therefore concentrations 
were calculated to make up 100µL when added to the cells and MTT solution. Solutions of 
the polymer as well as solutions of amantadine were added directly to the wells of the plate 
in a concentration range of 25µg/ml to 200µg/ml. Nanospheres were suspended in media. 
The hydrogel and nanosphere-composite were first submerged in PBS pH 7.4 and the elutes 
released into the PBS at various time periods over 96 hours were tested. A control 
formulation was also prepared.  
 
6.2.2.5.2.2. Testing of samples  
 
Culture media (60μL) was added to each well of the 96 well plate. Cells were allowed to 
attach and grow for 24 hours in an incubator (37˚C, 5% CO2). Test samples were then 
added to the wells and the plate was incubated for 24 hours.  
 
Positive and negative controls were used as described in Table 6.1. The MTT solution (5mg/ 
mL) was added to each well and the cells were left to incubate in the dark at 37⁰ C for 2-4 
hours. After incubation the medium was removed from each well and 200µl of 
dimethylsulphoxide (DMSO) was added to dissolve the formazan crystals. The plates were 
read at 540nm with a reference wavelength of 690nm using a plate reader. 
6.2.2.6. Utilisation of confocal microscopy to confirm the extent of cell uptake of 
nanospheres by NSC-34 cells 
6.2.2.6.1. Growing cells on cover slips 
Cells were grown on sterile cover slips (22 x 22mm). Briefly cover slips were sterilised by 
flaming and placed in petri dishes. Cells were diluted (1 in 20) with complete media and 
centrifuged. The supernatant was discarded and the pellet resuspended in complete media. 
Less than 1 mL of cell suspension was added to each cover slip and monitored over 12 
hours. Once the cells had attached to the cover slips, 2 mL of complete media was added. 
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6.2.2.6.2. Fixing of motor neuron cells onto cover slips 
A fixative was prepared using a 3% paraformaldehyde solution (using PBS, pH 7,4). This 
solution was prepared in a fume hood (not in sterile room) as it is a toxic substance that 
could contaminate cells. 
Media was aspirated from the petri dishes. The cover slips were rinsed with PBS 3 times to 
get rid of unwanted protein. After rinsing with PBS, a thin layer of PBS was placed on the 
petri dishes followed by an addition of 2 mL of fixative to cease all biological processes and 
preserve the cells. Cells were fixed for 15-30 minutes followed by a rinse with PBS 3-4 
times. The petri dishes were covered with parafilm and left in a fridge at 4°C for 48 hours. 
Cover slips were then mounted using 10% glycerol in PBS. 
6.2.2.7. High speed fluorescence microscopy for live imaging of uptake of 
nanospheres by NSC-34 cells  
 
A high speed fiber-optic fluorescence microscope (Cellvizio® LAB, coupled with Microprobes 
and ImageCell™ Software; Visualsonics and Mauna Kea Technologies, USA) was utilised 
for ex vivo cellular imaging to determine nanosphere uptake by NSC-34 cells. It provides an 
in situ dynamic fluorescence microscopy solution, generating key information on the manner 
and location in which a molecular compound is taken up at the cellular level. Fluorescein-
conjugated nanospheres were prepared (Figure 6.3). Each nanosphere suspension (0.5mL) 
was placed in a graduated sterile centrifuge tube. NSC-34 cell culture (1 mL), which was 
exposed to UV irradiation, was introduced into each tube followed by centrifugation of the 
cell cultures at 280xg in a high-speed table microcentrifuge (Model TG16-WS, Shanghai 
Ronbio Scientific Co., Ltd., China) and extraction of the supernatant. Thereafter, the cells 
were re-suspended in PBS (pH 7.4). The nanosphere-cell culture samples were incubated 
for 30 mins at 37oC; thereafter the samples were viewed, and images acquired at successive 
time intervals for determination of nanosphere-cell interactions.  
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Figure 6.3: Conjugating the FITC to the nanospheres. The beaker had to be covered with 
foil to keep the solution in the dark 
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6.3. Results and discussion 
6.3.1. Cell culturing 
The NSC-34 cell line typically contains small cells derived from mouse motor neurons and 
large multinucleated cells derived from mouse neuroblastoma. When they differentiate, 
NSC-34 cells become small cells with extended neuronal processes. This was evident when 
culturing occurred in flasks. However, once the cells were grown on cover slips only the 
small cells were observed without the extended neuronal processes. This could be as a 
result of the cells not growing in conditions where their growth could thrive i.e. on cover slips. 
It is also possible that the cells required more time to reach the stage where the extended 
neuronal processes started being visible due to the different surface the cells were made to 
grow on. 
                  
Figure 6.4: NSC-34 cells grown on cover slips. Small round cells were observed without the 
extended neuronal processes 
6.3.2. Cell viability 
NSC-34 cell viability was determined after exposure to different concentrations of 
amantadine, drug-loaded DTPA-bound nanospheres, drug-loaded nanospheres (without 
DTPA), the placebo (DTPA-bound nanospheres without drug) through an MTT assay. The 
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thermosensitive hydrogel and the nanosphere-hydrogel composite were also tested using 
the MTT assay at various time intervals. In the concentration dependent cytotoxic 
experiment (Figure 6.5) the cell viability of NSC-34 decreased with increasing concentration 
of the all components of the nanospheres. This indicates that the cytotoxicity of the 
nanospheres was in a concentration dependent manner. Results also showed that 
amantadine was more toxic in its conventional form than when encapsulated in the nano-
enabled drug delivery system with and without DTPA. This suggests that the nanospheres 
were able to expose the cells to less amantadine when compared to the directly added 
conventional drug and were able to release the amantadine slowly ensuring gradual 
exposure of the drug to the cells. The nano-enabled system without amantadine had no 
significant toxicity. 
The polymers used to prepare the nanospheres as well as the chelating ligand were also 
individually tested for cytotoxicity (Figure 6.6) at different concentrations. The results show 
that there was also an overall decrease in cell viability with increasing concentration 
confirming the results obtained in Figure 6.5 that the cytotoxicity is reliant on concentration. 
In the time dependent experiment to test the cytotoxicity of the nanospheres, 100µg/ml was 
selected as the concentration to investigate prolonged toxicity (Figure 6.7). Results show 
that there was a slight decrease in cell viability with increased incubation time. However, 
after 72 hours the cell viability almost levels out and stops decreasing. The hydrogel and the 
nanosphere-hydrogel composite were also tested for prolonged toxicity (Figure 6.7). They 
expressed similar results to the nanosphere formulation in terms of time dependent 
cytotoxicity. However, the hydrogel and the nanosphere-hydrogel composite showed less 
toxicity than the nanosphere formulation. There was insignificant difference in cytotoxicity 
between the hydrogel and the nanosphere-hydrogel composite. 
 
 
 
 
 
 
 
117 
 
 
          a)
1 2 3 4 5
V
ia
b
ili
ty
 o
f 
ce
lls
 (
%
)
0
20
40
60
80
100
120
1 - Control
2 - Amantadine
3 - DTPA-bound nanospheres (Placebo)
4 - Drug-loaded DTPA-bound nanospheres
5 - Drug-loaded nanospheres
 
         b)
1 2 3 4 5
V
ia
b
ili
ty
 o
f c
e
lls
 (
%
)
0
20
40
60
80
100
120
1 - Control
2 - Amantadine
3 - DTPA-bound nanospheres (Placebo)
4 - Drug-loaded DTPA-bound nanospheres
5 - Drug-loaded nanospheres
 
118 
 
               c)
1 2 3 4 5
V
ia
b
ili
ty
 o
f 
c
e
lls
 (
%
)
0
20
40
60
80
100
120
1 - Control
2 - Amantadine
3 - DTPA-bound nanospheres (Placebo)
4 - Drug-loaded DTPA-bound nanospheres
5 - Drug-loaded nanospheres
 
                d) 
1 2 3 4 5
V
ia
b
ili
ty
 o
f 
c
e
lls
 (
%
)
0
20
40
60
80
100
120
1 - Control
2 - Amantadine
3 - DTPA-bound nanospheres (Placebo)
4 - Drug-loaded DTPA-bound nanospheres
5 - Drug-loaded nanospheres
 
Figure 6.5: In vitro cytotoxicity of different concentrations of the various stages of the 
nanosphere formulation, including amantadine as the positive control and plain cells as 
negative control, after incubation for 48 hours; a) = 25µg/ml; b) = 50µg/ml; c) = 100µg/ml; d) 
= 200µg/ml 
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Figure 6.6 In vitro cytotoxicity of different concentrations of the polymers used for the 
nanosphere formulation, including DTPA, after incubation for 48 hours; A = 25µg/ml; B = 
50µg/ml; C = 100µg/ml; D = 200µg/ml 
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Figure 6.7: In vitro cytotoxicity of the complete nanospheres, the hydrogel and the 
nanosphere-hydrogel composite after incubation at different times; 1 = 12hrs; 2 = 24hrs; 3 = 
48hrs; 4 = 72hrs; 5 = 96hrs 
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6.3.3. Ex Vivo Uptake of Modified DTPA-Bound Nanospheres 
To investigate the effect of the DTPA on nanosphere uptake, ex vivo samples were 
characterised by fluorescence imaging. Results depicted high cellular uptake of the FITC-
labelled DTPA-bound nanospheres (Figure 6.8). Unmodified nanospheres showed no 
significant fluorescence activity. As discussed in Chapter 4 Section 4.3.6, the DTPA-bound 
nanospheres had a slightly increased size as compared to the unmodified nanospheres. 
Small nanoparticles sediment less than larger nanoparticles and their contact with cells is 
determined by diffusion and convection forces. Conversely, larger nanoparticles settle more 
rapidly due to the additional influence of sedimentation forces. Well plates containing the 
DTPA-bound nanospheres were found to show slight sedimentation. It has been reported 
that nanoparticles with a fast sedimentation rate show higher cellular uptake (Lison and 
Huaux, 2011).  
 
This study demonstrated that the modified DTPA-bound nanospheres had a greater cellular 
uptake. This result indicated that intracellular uptake of nanospheres was mediated by the 
DTPA conjugated onto the nanospheres. 
To supplement the uptake studies, fluorescent nanospheres were viewed under the 
magnification of the CellVizio® imaging system from 30 minutes to an hour. Figure 6.9 shows 
that DTPA-bound nanospheres were most efficiently internalised by the NSC-34 cells in 
comparison to the unmodified nanospheres. The unmodified nanospheres showed 
insignificant fluorescence further confirming the results observed in Figure 6.8. 
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Figure 6.8: Light and microscopy analysis of NSC-34 cell line incubated with FITC labelled 
a) DTPA-bound nanospheres; b) unmodified nanospheres 
  
a 
b 
a 
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Figure 6.9: CellVizio® imaging of fluorescent nanospheres taken between 30 minutes and 
an hour; a) DTPA-bound nanospheres; b) unmodified nanospheres. 
  
a) 
b) 
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6.4. Concluding remarks 
In conclusion, this study aimed to determine the effect of the components of the 
nanospheres as well as the elutes of the hydrogel and nanosphere-hydrogel composite on 
NSC-34 cells using an MTT assay. Concentration dependent studies as well as time 
dependent studies were performed and results showed that cytotoxicity relied both on 
concentration and time of incubation with the cells. It was also observed that the 
nanospheres were able to decrease toxicity of the study drug, amantadine, and the elutes of 
the hydrogel and nanosphere-hydrogel composite showed very little cytotoxicity towards the 
NSC-34 cell line. 
Cellular uptake studies were also performed. The efficiency of DTPA in increasing the 
internalisation of the nanospheres by the NSC-34 cells was investigated using fluorescence 
microscopy and CellVizio® imaging. Results showed an increased uptake of the 
nanospheres that were modified with DTPA compared to unmodified nanospheres. DTPA 
therefore, mediated the cellular internalisation of the nanospheres. 
The nanosphere-hydrogel composite thus presented promising results throughout the in vitro 
testing of the system.  
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CHAPTER SEVEN 
CONCLUSIONS AND RECOMMENDATIONS 
 
7.1. Conclusions 
The challenges with managing neurodegenerative disorders due to, among other reasons, 
the BBB have brought forth the need for innovative development of a drug delivery system 
that will overcome this obstacle. ALS has a poor prognosis and numerous therapeutic 
agents have failed to produce much desired results. This study was aimed to design and 
develop a polymer based nano-enabled drug system for the treatment of ALS. In order to 
fabricate optimal nanospheres, preformulation studies were performed with poly (D,L) lactide 
and various polymethacrylates to determine the best combination. The anionic 
polymethacrylate, Eudragit® L100, was selected as it produced the best results overall, in 
combination with PDLLA. Amantadine, an antiviral drug commonly used to treat influenza A 
was chosen as the study drug because it has shown neuroprotective properties. The 
nanospheres were prepared using the double-emulsion solvent evaporation method. 
Statistical optimisation was performed employing the 3-factor Box Behnken design after 
variables (amount of L100, sonication time, solvent volume) were identified. The Box-
Behnken design was used to determine the best nanosphere formulation in relation to 
particle size, zeta potential, drug entrapment efficiency and drug release. Dynamic light 
scattering was used to determine the particle size, zeta potential and polydispersity index of 
the nanosphere formulations. All experiments were investigated under simulated 
physiological conditions i.e. at pH 7.4. Constructed surface plots were used to elucidate the 
relationship between the variables. The physicochemical properties of the optimised 
nanospheres were investigated employing various experiments. The surface morphology of 
the nanospheres was characterized using TEM. The optimised formulation had an average 
zeta size of 80.41nm, zeta potential of -27.7mV, drug entrapment of 50.92% and a Mean 
Dissolution Time (MDT) of 19.3 hours. All these values were exceedingly close to the values 
predicted statistically.  
The optimised nanospheres were conjugated to the chelating ligand, DTPA, to increase the 
uptake of the nanospheres by cells. The DTPA-bound nanospheres had a size of 105.6nm, 
a PdI of 0.240 and zeta potential of -31.0mV. The conjugation efficiency was at 74%. 
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The nanospheres required a carrier in order to administer them to the brain. A 
thermosensitive hydrogel using ε-caprolactone and N-vinylcaprolactam was formulated 
employing solution polymerisation and investigated. The hydrogel was tested using 
oscillatory rheology and FTIR. The formulation displayed typical thermoresponsive behaviour 
with a Lower Critical Solution Temperature (LCST). FTIR spectra showed the blending of the 
two polymers to form the hydrogel. It was also revealed that there was a minor alteration in 
the bonds present in the hydrogel when it transitioned from liquid to sol state due to weak 
physical bonds. SEM showed that the hydrogel did not have a uniform morphology 
throughout its composition. 
The hydrogel formulation was blended with the amantadine-loaded DTPA-bound 
nanospheres to form a homogenous solution. The nanosphere-hydrogel composite was 
tested for drug release. The hydrogel was able to greatly decrease the rate of release of 
amantadine and proved to be an efficient carrier of the amantadine-loaded nanospheres. 
All the components of the drug delivery system were tested for possible cytotoxicity on NSC-
34 cells. The system showed little cytotoxicity and demonstrated that the nano-enable 
system decreased the toxicity of the conventional amantadine.  
In conclusion, in vitro and ex vivo research showed promising results with highly stable 
nanospheres and an efficient thermosensitive hydrogel as a carrier.  
7.2. Recommendations 
There is currently not enough research into developing a nano-enabled system specific for 
ALS. It is recommended that more investigations into nanotechnology for the treatment of 
ALS should be done. Moreover, further research into amantadine should be considered as it 
has shown promising results in other neurodegenerative disorders. 
In addition, more in depth studies (which would include various characterisation) on the 
difference between nanosphere preparation with cationic PMAs and anionic PMAs in 
combination with PDLLA would be useful for broader investigations. Further research can 
also be done to improve the drug entrapment efficiency as well as the drug release from the 
nanospheres. The drug release rate of amantadine from the nanosphere-hydrogel composite 
was however much lower. The gelation temperature of the hydrogel is recommended to be 
increased from 18.45°C to a temperature closer to body temperature. 
Cell studies involving the investigation of the chelating efficiency of DTPA should also be 
performed because although it was proven that it increases the uptake of the nanospheres 
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its other function crucial to addressing ALS i.e. removing ions proposed to be involved in 
oxidative stress was not tested. It was just assumed that it would perform its chelating 
function from reading previous literature. Additionally, micrographs of NSC-34 cells in the 
presence of various nanospheres would be valuable for more expansive comparisons. 
It would be highly beneficial to further investigate the nanosphere-hydrogel composite in in 
vivo studies. In vivo studies would provide additional pharmacokinetic data and determine 
the efficacy of the nanosphere-hydrogel composite in a suitable animal model. Such a study 
would also provide information on any unforeseen side effects which cannot be determined 
by in vitro studies alone. There are a few rodent models of ALS which include SOD1 rodent 
models, TDP-43 models, FUS models and VCP models that can be employed (McGoldrick 
et al., 2013). 
The nanosphere-hydrogel composite could be used to deliver other therapeutic agents for 
various other disorders that are difficult to treat due to the intricacy of the agents in reaching 
the target site. Cancer for example requires aggressive treatments which results in healthy 
tissue being exposed to chemotherapeutics. The drug delivery system designed and 
prepared for this study could be highly useful in delivering chemotherapeutics to cancerous 
cells, while avoiding contact with healthy cells. This could improve the efficiency of these 
therapeutics as well as patient compliance.  
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